cms.bioaccessla.com

Category: Preparing for First-In-Human Studies

Offers insights and best practices for Medtech, Biopharma, and Radiopharma companies preparing for their first-in-human clinical trials.

  • 4 Best Practices for First-in-Human Studies in Cuba

    4 Best Practices for First-in-Human Studies in Cuba

    Introduction

    Navigating Cuba’s first-in-human studies poses both significant challenges and remarkable opportunities for sponsors. With a regulatory framework known for its efficiency and a commitment to patient safety, it’s essential for sponsors to grasp the nuances of this environment to thrive.

    How can sponsors leverage Cuba’s strategic advantages to streamline their clinical trials while ensuring compliance and ethical standards are met? This article explores best practices that can enhance the likelihood of successful outcomes in this dynamic setting. By embracing these best practices, sponsors can position themselves for success in this evolving landscape.

    Understand Regulatory Framework for FIH Studies in Cuba

    Understanding the regulatory framework for the first-in-human study Cuba is essential for sponsors aiming to navigate this unique landscape effectively. The approval process for clinical trials in Cuba is notably efficient, typically taking between 30 to 90 days. This timeline varies based on the study’s complexity and the completeness of the submitted documentation. This accelerated timeline is a significant benefit for sponsors looking to commence studies swiftly. CECMED was recognized as a Level 4 National Regulatory Authority in 2011, highlighting its credibility in overseeing clinical studies. With extensive experience in the region, Bioaccess® empowers sponsors to meet compliance requirements efficiently, ensuring a smoother path forward.

    All studies must adhere to ICH-GCP standards, ensuring that the rights, safety, and well-being of participants are protected. Failure to comply can jeopardize trust with local authorities and international stakeholders, complicating interactions throughout the study process. For instance, the Soberana 02 vaccine demonstrated a 91.2% efficacy after two doses, showcasing the effectiveness of trials conducted under CECMED’s oversight. Bioaccess® supports sponsors in meeting these compliance requirements efficiently, leveraging its extensive experience in the region.

    Sponsors must prepare comprehensive documentation, including:

    • A detailed research protocol
    • Informed consent forms
    • Safety monitoring plans

    These documents must be submitted in both Spanish and English to facilitate review by CECMED, ensuring clarity and thoroughness in the application. Bioaccess® assists in the preparation of these documents, ensuring they meet local regulatory standards and expedite the review process.

    In addition to CECMED authorization, projects must also receive clearance from an independent ethics committee, which assesses the ethical implications of the proposed research. This step is vital for maintaining ethical standards and protecting participant rights. As Olga Lidia Jacobo-Casanueva, Director of CECMED, emphasizes, ‘Pediatric clinical studies require even more rigor due to the ethical factors involved.’ This underscores the importance of ethical considerations in research. Bioaccess®’s expertise in navigating these ethical requirements further enhances the likelihood of timely approvals.

    By thoroughly understanding these regulatory requirements and leveraging the support of Bioaccess®, sponsors can streamline their submission process and enhance the likelihood of timely approvals, ultimately accelerating their path to conducting first-in-human study Cuba.

    This flowchart outlines the steps sponsors must take to navigate the regulatory framework for first-in-human studies in Cuba. Each box represents a key stage in the process, from preparing necessary documents to obtaining approvals. Follow the arrows to see how each step leads to the next, ensuring a clear understanding of the workflow.

    Implement Early Feasibility Studies to Assess Viability

    Navigating the complexities of early feasibility assessments (EFA) is essential for the successful advancement of medical devices and biopharmaceuticals, particularly in the context of the first-in-human study Cuba. Here are key considerations for implementing EFS:

    • Objective Setting: Clearly define the objectives of the EFS, focusing on critical aspects such as safety, device functionality, and preliminary efficacy. This clarity helps shape the research design and makes it easier to evaluate outcomes effectively.
    • Regulatory Pathway: Engage with CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos) early in the process to understand the specific requirements for EFS submissions. This includes determining eligibility for expedited review under the Cuban regulatory framework, which can significantly shorten approval timelines to as little as 4-8 weeks.
    • Site Selection: Choose clinical sites experienced in conducting EFS. bioaccess® maintains a network of pre-qualified sites across Latin America, including Colombia, Brazil, and Mexico, that can expedite patient recruitment and streamline data collection, ensuring compliance with ICH-GCP standards.
    • Patient Engagement: How can we involve potential participants early in the design process to gather insights on their needs and preferences? This proactive engagement can enhance recruitment strategies and improve participant retention rates, addressing common challenges faced by companies in implementing EFS.
    • Data Collection and Analysis: Utilize robust data gathering techniques to collect preliminary information that can guide future study designs. Examining this data is essential for recognizing necessary changes to the investigational product or protocol.

    By implementing EFS, sponsors can mitigate risks and enhance the likelihood of success in the first-in-human study Cuba trials, leveraging the region’s strategic advantages in speed and cost efficiency. Embracing EFS not only mitigates risks but also positions sponsors for a more efficient and successful clinical development journey.

    This flowchart outlines the steps to implement early feasibility studies. Each box represents a key consideration in the process, and the arrows show how each step connects to the next, guiding you through the implementation journey.

    Develop Targeted Patient Recruitment Strategies

    Effective patient recruitment is not just important; it’s essential for the success of first-in-human study Cuba, especially in unique healthcare environments. In this context, tailored strategies are necessary to optimize enrollment. Here are best practices for developing targeted patient recruitment strategies:

    • Understand the Local Healthcare Landscape: Familiarize yourself with the Cuban healthcare system, which emphasizes primary care. Building relationships with local healthcare providers, including family doctors and hospitals, can facilitate referrals and enhance trust among potential participants. Based on a survey, 73% of patients prefer to learn about clinical study opportunities from their doctor’s office, highlighting the significance of these relationships.
    • Utilize Community Engagement: Think about connecting with community organizations and patient advocacy groups to spread the word about your clinical study. This grassroots method can clarify the process and promote involvement. Collaborating with local leaders and influencers builds credibility and trust within the community, which is vital for recruitment success.
    • Leverage Digital Platforms: Utilize social media and online platforms to reach potential participants effectively. Tailored messaging that resonates with the local population can significantly enhance recruitment efforts. However, it’s essential to balance digital outreach with traditional methods, as over-reliance on digital platforms may overlook segments of the population that prefer direct communication.
    • Incentivize Participation: Consider offering incentives for participation, such as transportation assistance or compensation for time and travel. This approach can help reduce barriers to participation, especially for patients in rural areas who may encounter logistical challenges in accessing study sites. Logistical challenges often hinder patient participation, particularly for those in rural areas. Financial support can significantly improve enrollment rates and participant retention.
    • Monitor and Adapt: Continuously monitor recruitment progress and be prepared to adapt strategies as needed. Analyzing recruitment data can provide insights into which methods are most effective and where adjustments may be necessary. This iterative approach ensures that recruitment strategies remain responsive to the evolving needs of the study and the patient population.
    • Compliance with Authorities: Be aware of the relevant oversight bodies such as INVIMA and their requirements for clinical trials conducted in that region. Grasping the compliance landscape, including ICH-GCP standards and submission pathways, is essential for ensuring that recruitment strategies align with oversight expectations.

    By embracing these strategies, you not only improve recruitment but also contribute to the advancement of clinical research in Cuba. This proactive approach addresses the unique challenges of the Cuban healthcare landscape while leveraging the strengths of community engagement and digital outreach to optimize recruitment outcomes.

    Each box represents a key strategy for improving patient recruitment. Follow the arrows to see how these strategies connect and build upon each other to enhance recruitment efforts.

    Align Regulatory Strategies with Clinical Trial Execution

    Aligning compliance strategies with clinical study execution is crucial for the success of the first-in-human study Cuba, as regulatory challenges can significantly impact timelines. Here are key practices to ensure this alignment:

    • Early Regulatory Engagement: Initiate discussions with CECMED (Centro para el Control Estatal de Medicamentos, Equipos y Dispositivos Médicos) early in the trial design process. This proactive approach clarifies expectations and requirements, assisting in identifying potential hurdles before they occur. Navigating the regulatory landscape can be daunting, especially when unexpected hurdles arise during the approval process, which can greatly streamline the approval process and possibly shorten timelines for approval.
    • Integrated Project Management: Utilize an integrated project management approach that incorporates compliance timelines, including Brazil’s 4-8 week ethics approval timeline, into the overall study timeline. This guarantees that all team members are informed of compliance milestones, such as submission deadlines and approval timelines, enabling improved planning and resource distribution. This proactive approach not only streamlines the approval process but also enhances the overall efficiency of the study execution.
    • Documentation and Compliance: Maintain meticulous documentation of all submissions and communications with CECMED. This approach ensures that we stick to ICH-GCP standards while also fostering transparency and accountability throughout the study, which is essential for establishing trust with oversight bodies. Understanding the documentation requirements of INVIMA and COFEPRIS can also enhance compliance strategies.
    • Training and Education: Provide comprehensive instruction for the clinical study team on compliance requirements and best practices specific to Cuba. This equips all team members to navigate the regulatory landscape effectively, ensuring adherence to local laws and international standards. Collaboration with statisticians during this training can enhance methodological integrity and improve trial outcomes. Insights from early feasibility studies conducted in Brazil and Mexico can serve as valuable case studies for training.
    • Feedback Loops: Establish feedback loops between regulatory affairs and clinical operations teams. Regular communication can aid in identifying issues early and enable prompt resolutions, ensuring that the study remains on track and compliant with CECMED’s evolving expectations. Drawing on experiences from successful studies in Brazil and Mexico can provide practical examples for overcoming common challenges.

    By prioritizing regulatory alignment, sponsors can not only navigate challenges but also pave the way for groundbreaking advancements in clinical research in Cuba.

    The central idea is about aligning regulatory strategies with clinical trials. Each branch represents a key practice that contributes to this alignment, and the sub-branches provide more details on how to implement these practices effectively.

    Conclusion

    First-in-human studies in Cuba offer both significant potential and formidable challenges that demand strategic foresight. Understanding the regulatory framework and aligning compliance strategies with clinical trial execution are crucial for sponsors aiming to enhance their success rates. Thorough preparation and local expertise are essential for overcoming obstacles and ensuring smooth clinical trial execution.

    Key practices highlighted include:

    1. Early engagement with regulatory authorities like CECMED
    2. Implementing early feasibility studies to assess viability
    3. Developing targeted patient recruitment strategies

    These elements streamline the approval process and foster trust and collaboration within the local healthcare system. Additionally, leveraging community engagement and digital platforms optimizes recruitment efforts, ensuring that trials are well-populated and representative of the target demographics.

    The success of first-in-human studies in Cuba relies on a proactive and informed approach. Adopting best practices that emphasize regulatory alignment, ethical considerations, and effective patient recruitment positions sponsors for groundbreaking advancements in clinical research. Engaging with local partners like Bioaccess® enhances compliance and operational efficiency, paving the way for innovative medical solutions that benefit participants and the broader healthcare landscape.

    Frequently Asked Questions

    What is the approval timeline for clinical trials in Cuba?

    The approval process for clinical trials in Cuba typically takes between 30 to 90 days, depending on the study’s complexity and the completeness of the submitted documentation.

    What organization oversees clinical studies in Cuba?

    The Center for State Control of Medicines, Equipment and Medical Devices (CECMED) oversees clinical studies in Cuba and was recognized as a Level 4 National Regulatory Authority in 2011.

    What standards must all studies in Cuba adhere to?

    All studies must adhere to International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards to ensure the rights, safety, and well-being of participants are protected.

    What documentation is required for clinical trial submissions in Cuba?

    Sponsors must prepare comprehensive documentation, including a detailed research protocol, informed consent forms, and safety monitoring plans, which must be submitted in both Spanish and English.

    Why is it important to comply with regulatory requirements in Cuba?

    Compliance with regulatory requirements is crucial as failure to do so can jeopardize trust with local authorities and international stakeholders, complicating interactions throughout the study process.

    What additional clearance is needed besides CECMED authorization?

    Projects must also receive clearance from an independent ethics committee that assesses the ethical implications of the proposed research, which is vital for maintaining ethical standards and protecting participant rights.

    How does Bioaccess® assist sponsors in the regulatory process in Cuba?

    Bioaccess® supports sponsors by helping them prepare the necessary documentation to meet local regulatory standards and expedite the review process, leveraging its extensive experience in the region.

    What specific considerations are there for pediatric clinical studies in Cuba?

    Pediatric clinical studies require more rigor due to ethical factors involved, emphasizing the importance of adhering to ethical standards during research.

    How can understanding the regulatory framework benefit sponsors?

    By thoroughly understanding the regulatory requirements and leveraging the support of Bioaccess®, sponsors can streamline their submission process and enhance the likelihood of timely approvals, accelerating their path to conducting first-in-human studies in Cuba.

    List of Sources

    1. Understand Regulatory Framework for FIH Studies in Cuba
      • scielosp.org (https://scielosp.org/article/medicc/2021.v23n3-4/9-14)
      • Number of clinical trials by year, country, region and income group (https://who.int/observatories/global-observatory-on-health-research-and-development/monitoring/number-of-clinical-trials-by-year-country-who-region-and-income-group)
    2. Implement Early Feasibility Studies to Assess Viability
      • jmir.org (https://jmir.org/2025/1/e77982)
      • How does an Early Feasibility Study differ from a Pivotal Study? | MED Institute (https://medinstitute.com/blog/how-does-an-early-feasibility-study-differ-from-a-pivotal-study)
      • Early Feasibility Studies: Top 6 Considerations | MED Institute (https://medinstitute.com/blog/early-feasibility-studies-top-6-considerations)
      • A Decade of Innovation in Medical Device Testing – Medical Device Innovation Consortium (https://mdic.org/celebrating-early-feasibility-studies-10-year-journey)
    3. Develop Targeted Patient Recruitment Strategies
      • linical.com (https://linical.com/articles-research/keys-to-maximize-patient-recruitment)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • 25+ useful clinical trial recruitment statistics for better results (https://antidote.me/blog/25-useful-clinical-trial-recruitment-statistics-for-better-results)
      • Patient Recruitment Strategies for Effective Clinical Trials | bioaccess® (https://bioaccessla.com/blog/patient-recruitment-strategies-for-effective-clinical-trials)
    4. Align Regulatory Strategies with Clinical Trial Execution
      • Patient Engagement Statistics: Data That Proves Impact (https://nclusiv.co.uk/blog/f/patient-engagement-statistics-data-that-proves-impact)
      • What differentiates clinical trial statistics from preclinical methods and why robust approaches matter – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC11327279)
      • How Regulatory Compliance for Clinical Trials Drives Better Outcomes (https://rubixls.com/post/how-regulatory-compliance-for-clinical-trials-drives-better-outcomes)
      • omnicureresearch.com (https://omnicureresearch.com/understanding-regulatory-requirements-for-clinical-trials)

  • Best Practices for FIH Clinical Trials in Costa Rica

    Best Practices for FIH Clinical Trials in Costa Rica

    Introduction

    First-in-human (FIH) clinical trials in Costa Rica offer a unique blend of challenges and opportunities for MedTech and Biopharma companies. With a robust regulatory framework governed by Law 9234 and the oversight of the National Council for Health Research (CONIS), understanding these dynamics is crucial for successful trial execution. This article explores best practices that can streamline the approval process, enhance patient recruitment, and ensure compliance with ICH-GCP standards. Ultimately, this positions Costa Rica as a strategic hub for early-stage research in Latin America. By leveraging local insights and regulatory expertise, how can companies enhance trial outcomes and expedite market entry for innovative therapies?

    Understand the Regulatory Landscape for FIH Trials in Costa Rica

    Understanding Costa Rica’s regulatory framework is essential for successful FIH clinical trial Costa Rica in the region. Governed by Law 9234, enacted in 2014, this framework establishes comprehensive requirements for biomedical research. The National Council for Health Research (CONIS) supervises the approval process, ensuring compliance with ethical and scientific standards. For first-in-human (FIH) studies, submitting a comprehensive application is crucial. This includes the study protocol, informed consent forms, and evidence of compliance with ICH-GCP standards.

    The approval process varies in duration, often taking several months depending on study complexity. However, CONIS usually processes applications within 30 to 90 days, making this region an appealing choice for quick initiation compared to others. In 2026, regulators will expect risk management to be visible throughout the study lifecycle. Understanding these guidelines helps navigate the approval process more smoothly and enhances the credibility of the data collected, which is vital for subsequent submissions to authorities like the FDA or EMA.

    This oversight framework, along with a dedication to participant safety, comprehensive documentation, and special attention to at-risk populations, establishes Costa Rica as a key site for FIH clinical trial Costa Rica in early-stage research initiatives in Latin America. How can insights from bioaccess® through the Global Trial Accelerators™ empower Medtech startups with essential market access strategies and regulatory updates? By leveraging bioaccess® insights, Medtech startups can significantly enhance their chances of success in clinical research.

    This flowchart shows the steps needed to get approval for clinical trials. Start with your application, follow the steps, and see how long the process might take. Green means you're on track, while red indicates you may need to make changes.

    Implement Early Feasibility Studies to Validate Concepts

    In the competitive landscape of MedTech and Biopharma, validating concepts through Early Feasibility Studies (EFS) is not just beneficial; it’s essential. EFS allows sponsors to assess the safety and functionality of their devices or drugs. This evaluation occurs in a controlled setting with a limited participant pool, usually enrolling ten or fewer subjects. In Costa Rica, the fih clinical trial costa rica can conduct an EFS that yields FDA-bridgeable data within 9 to 12 months, significantly accelerating the time to market compared to traditional pathways.

    To effectively implement EFS, sponsors should collaborate with local CROs that possess in-depth knowledge of the region’s regulatory landscape, including authorities such as ANVISA and INVIMA, and established networks of pre-qualified trial sites. This partnership boosts recruitment efficiency, addressing the frequent challenge of patient enrollment, which is a significant factor in the high failure rate of trials-over 90% due to recruitment problems and other inefficiencies.

    Moreover, EFS offers greater flexibility than pivotal studies, allowing for more frequent protocol and device modifications as new information emerges. This adaptability is crucial in the early stages of device development, enabling companies to refine their approaches based on initial clinical experiences. By utilizing the EFS framework, MedTech and Biopharma companies can navigate the regulatory requirements established by local authorities, ensuring adherence to ICH-GCP standards and facilitating a smoother transition to first-in-human studies.

    Furthermore, sponsors can gain from the overall cost reduction of 30%, enabling them to reinvest those savings into R&D or their next funding milestone. In conclusion, executing EFS strategically not only shortens the time needed to gather crucial medical data but also empowers companies to make informed decisions about their product development, enhancing their chances for successful market entry.

    This flowchart outlines the steps involved in implementing Early Feasibility Studies. Start at the top with the main goal, then follow the arrows to see how each step connects to the next, leading to successful outcomes in product development.

    Select Pre-Qualified Clinical Trial Sites for Enhanced Efficiency

    Selecting the right clinical research sites is a pivotal factor in the success of the FIH clinical trial in Costa Rica. Utilizing a network of pre-qualified sites can significantly enhance operational efficiency and reduce timelines. These sites adhere to ICH-GCP standards and possess the essential infrastructure to conduct studies effectively. Sponsors must prioritize sites with expertise in FIH studies and a proven history of patient recruitment. Have you considered how the right site selection can impact your study’s success? Over 30% of research sites fail to enroll even one patient, underscoring the critical need for careful site selection to avoid costly delays in research timelines.

    Partnering with local CROs such as bioaccess® is essential for streamlining this process, given their established relationships with over 50 pre-qualified sites across the country. This strategic collaboration not only accelerates site activation but also ensures that the quality of data collected meets regulatory expectations, ultimately supporting faster regulatory submissions. bioaccess®’s Innovation Runway, crafted specifically for FIH studies, allows MedTech, Biopharma, and Radiopharma startups to traverse the development pathway 40% faster, ensuring they can secure funding and connect with strategic partners effectively. This is especially crucial considering that 90% of healthcare startups fail due to lack of capital before producing the necessary medical data.

    In Costa Rica, the approval process is supported by local entities like INVIMA, guaranteeing that studies can advance smoothly while meeting compliance standards. By concentrating on these pre-qualified locations, sponsors can utilize the benefits of speed, cost-effectiveness, and improved patient recruitment, establishing Latin America as a strategic option for early-stage research. As noted, “Patient-centered protocols, which genuinely address the needs, comfort, and preferences of participants, are not just regulatory necessities but critical to the integrity of the research process.” Furthermore, the Global Trial Accelerators™ framework assists this initiative, offering crucial insights and strategies for navigating the clinical research landscape. Ultimately, the right partnerships and site selections can redefine the landscape of clinical research in Latin America, paving the way for groundbreaking advancements in healthcare.

    This flowchart illustrates the steps involved in selecting the right clinical trial sites. Each box represents a key action or decision, and the arrows show how these steps connect to lead to better outcomes in clinical research.

    Develop Targeted Patient Recruitment Strategies

    Effective patient recruitment is the cornerstone of successful first-in-human studies in the region, yet many sponsors struggle to navigate the complexities involved. Sponsors should implement targeted recruitment strategies that capitalize on local demographics and established healthcare networks. Engaging with community members through outreach initiatives, utilizing digital marketing campaigns, and forming partnerships with local healthcare providers can significantly enhance visibility and attract eligible participants.

    Implementing a two-step prescreening process will streamline recruitment, allowing sponsors to identify potential candidates early and confirm their eligibility efficiently. Collaborating with local patient advocacy groups can further facilitate outreach efforts and foster trust within the community, which is crucial for participant engagement.

    Adopting these strategies will empower sponsors to significantly reduce enrollment timelines, ensuring efficient study completion. This not only speeds up access to essential clinical data but also aligns with the approval processes for the fih clinical trial costa rica established by local authorities such as the Ministry of Health, which stresses adherence to ICH-GCP standards. Harnessing the unique demographic landscape and healthcare infrastructure of Costa Rica can transform the outcomes of first-in-human studies, paving the way for groundbreaking advancements in clinical research.

    This flowchart outlines the key strategies for recruiting patients in clinical studies. Start at the top with the main goal, then follow the arrows to see the specific strategies and actions that can help sponsors effectively engage with potential participants.

    Ensure Compliance with ICH-GCP Standards Throughout Trials

    Adhering to ICH-GCP standards is not just a regulatory obligation; it’s a cornerstone for successful fih clinical trial costa rica studies. These guidelines ensure that studies are designed, executed, and reported with the utmost ethical and scientific integrity. Sponsors need to implement comprehensive training programs for all study staff to achieve this, focusing on ICH-GCP principles to enhance their understanding and adherence to these standards. Regular audits and monitoring are essential to identify and address any compliance issues swiftly. This ensures that all study activities are meticulously documented, which is crucial for demonstrating compliance during assessments by authorities such as the Costa Rican Ministry of Health.

    Prioritizing ICH-GCP compliance protects participant safety. It also significantly enhances the credibility of study data. This credibility is essential for enabling smoother submissions and approvals, ultimately accelerating the pathway to market for innovative therapies. Successful trials that comply with ICH-GCP standards have demonstrated enhanced outcomes, including higher rates of approval and shortened timelines for delivering new treatments to patients. Thus, investing in robust training and compliance measures is not just a regulatory requirement but a strategic advantage in the competitive landscape of clinical research in Latin America.

    This flowchart outlines the steps to ensure compliance with ICH-GCP standards. Each box represents a key action or outcome, showing how they connect to enhance the integrity and success of clinical trials.

    Conclusion

    Navigating the complexities of first-in-human (FIH) clinical trials in Costa Rica is crucial for MedTech and Biopharma companies seeking success in early-stage research. Costa Rica stands out as a strategic hub for clinical trials due to its supportive regulatory framework. Efficient patient recruitment strategies and the implementation of Early Feasibility Studies (EFS) further enhance this position. By leveraging local expertise and infrastructure, sponsors can significantly improve their chances of successful outcomes and expedite the path to market.

    Key insights from this discussion highlight the importance of understanding the regulatory landscape governed by Law 9234 and the role of the National Council for Health Research (CONIS) in overseeing trial approvals. Implementing EFS allows for rapid validation of concepts, while adherence to ICH-GCP standards ensures that studies maintain high ethical and scientific integrity. Moreover, selecting pre-qualified clinical trial sites and employing targeted patient recruitment strategies can significantly reduce timelines and improve operational efficiency.

    With the growing demand for innovative therapies, MedTech and Biopharma companies have a unique opportunity to establish a strong presence in Costa Rica. By embracing the outlined best practices, organizations can navigate regulatory pathways effectively while capitalizing on the region’s cost efficiency and patient recruitment advantages. Engaging with local contract research organizations and fostering community partnerships will further enhance these efforts, ultimately driving advancements in healthcare and improving patient outcomes throughout Latin America.

    Frequently Asked Questions

    What is the regulatory framework for first-in-human (FIH) trials in Costa Rica?

    The regulatory framework for FIH trials in Costa Rica is governed by Law 9234, enacted in 2014, which establishes comprehensive requirements for biomedical research. The National Council for Health Research (CONIS) supervises the approval process to ensure compliance with ethical and scientific standards.

    What is required for submitting an application for FIH studies in Costa Rica?

    A comprehensive application is crucial for FIH studies, including the study protocol, informed consent forms, and evidence of compliance with ICH-GCP standards.

    How long does the approval process for FIH trials typically take in Costa Rica?

    The approval process can take several months, but CONIS usually processes applications within 30 to 90 days, making Costa Rica an appealing choice for quick initiation compared to other regions.

    What are the expectations for risk management in FIH studies by 2026?

    By 2026, regulators will expect risk management to be visible throughout the study lifecycle, which is essential for enhancing the credibility of the data collected.

    How do Early Feasibility Studies (EFS) benefit MedTech and Biopharma sponsors?

    EFS allows sponsors to assess the safety and functionality of their devices or drugs in a controlled setting with a limited participant pool, yielding FDA-bridgeable data within 9 to 12 months, significantly accelerating time to market.

    What is the role of local Contract Research Organizations (CROs) in conducting EFS?

    Collaborating with local CROs that have in-depth knowledge of the regulatory landscape and established networks of pre-qualified trial sites boosts recruitment efficiency and addresses common challenges in patient enrollment.

    How does EFS provide flexibility compared to pivotal studies?

    EFS allows for more frequent protocol and device modifications as new information emerges, which is crucial in the early stages of device development.

    What are the financial benefits of executing EFS strategically?

    Executing EFS can lead to an overall cost reduction of 30%, enabling sponsors to reinvest those savings into research and development or their next funding milestone.

    How does the EFS framework facilitate adherence to regulatory requirements?

    By utilizing the EFS framework, sponsors can ensure compliance with ICH-GCP standards and facilitate a smoother transition to first-in-human studies, navigating the regulatory requirements established by local authorities.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Costa Rica
      • eccrt.com (https://eccrt.com/blog_post/clinical-trial-regulations-in-2026-what-to-look-out-for-and-how-to-prepare)
      • linkedin.com (https://linkedin.com/pulse/navigating-clinical-research-regulations-costa-rica-soto-md-msc–lls6e)
    2. Implement Early Feasibility Studies to Validate Concepts
      • Early Feasibility Studies (EFS) Program (https://fda.gov/medical-devices/investigational-device-exemption-ide/early-feasibility-studies-efs-program)
      • Early feasibility studies on devices: “doing it sooner” to avoid trial failure | Meditrial (https://meditrial.net/2022/09/early-feasibility-studies-on-devices-doing-it-sooner-to-avoid-trial-failure)
      • How does an Early Feasibility Study differ from a Pivotal Study? | MED Institute (https://medinstitute.com/blog/how-does-an-early-feasibility-study-differ-from-a-pivotal-study)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
    3. Select Pre-Qualified Clinical Trial Sites for Enhanced Efficiency
      • Optimizing Site Selection and Management for Clinical Trial Success (https://studypages.com/blog/optimizing-site-selection-and-management-for-clinical-trial-success)
      • biobostonconsulting.com (https://biobostonconsulting.com/top-5-alarming-statistics-you-must-know-about-clinical-trial-site-selection)
      • New York Times Article on Clinical Trials Features Quote from the Alliance for Aging Research – Alliance for Aging Research (https://agingresearch.org/blog/new-york-times-article-on-clinical-trials-features-quote-from-the-alliance-for-aging-research)
      • ccrps.org (https://ccrps.org/clinical-research-blog/the-importance-of-ich-gcp)
    4. Develop Targeted Patient Recruitment Strategies
      • totaldiversity.com (https://totaldiversity.com/clinical-study-recruitment)
      • curebase.ai (https://curebase.ai/resources/articles/clinical-trial-patient-recruitment-guide)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • clariness.com (https://clariness.com/resource/patient-recruitment-in-clinical-trials)
      • Patient Recruitment Strategies for Effective Clinical Trials | bioaccess® (https://bioaccessla.com/blog/patient-recruitment-strategies-for-effective-clinical-trials)
    5. Ensure Compliance with ICH-GCP Standards Throughout Trials
      • ccrps.org (https://ccrps.org/clinical-research-blog/why-good-clinical-practice-training-is-essential-for-clinical-trials)
      • thetrainingassociates.com (https://thetrainingassociates.com/future-of-compliance-training)
      • icbiocro.com (https://icbiocro.com/ich-gcp-compliant-clinical-trials-ensuring-ethical-and-high-quality-research)
      • Mastering GCP Compliance in Clinical Trials: Expert Insights (https://biobostonconsulting.com/mastering-gcp-compliance-in-clinical-trials-expert-insights-from-development-consulting)

  • 5 Questions Every MedTech Team Asks Before Running Their First-in-Human Trial in Latin America

    On May 8, 2026, 98 MedTech professionals from 17 countries joined our Friday In Focus webinar on running first-in-human (FIH) clinical trials in Latin America. 59% stayed past 46 minutes in a 62-minute session — and they didn’t ask curiosity questions. They asked execution questions: country selection, ethics, FDA acceptability, statistical power, step-by-step playbooks for medical device sponsors who are actively planning their first FIH outside the United States.

    If you’re evaluating whether to run your next first-in-human study in Latin America, here are the five questions your peers pushed hardest on — and how to think about each one before you commit to a country, an ethics committee, or an FDA submission strategy.

    1. Which country in Latin America is the easiest?

    This was the first question out of the gate, asked by Rocío Paublete (Sweden, PMCF & Clinical Investigation Project Manager) and echoed throughout the chat. The honest answer is: it depends on what you’re optimizing for.

    “Easy” decomposes into three orthogonal dimensions:

    • Patient recruitment speed — how quickly you can enroll the first 5–30 patients for an FIH or early feasibility study. Colombia, Mexico, and Brazil typically lead here because of dense urban hospital networks and high physician engagement with research.
    • Ethics committee turnaround — how long the IRB/CEI review cycle takes from submission to approval. Chile and Costa Rica run faster review cycles than Brazil, where amendments through CONEP can stretch.
    • Regulatory authority predictability — INVIMA (Colombia), ANVISA (Brazil), COFEPRIS (Mexico), ANMAT (Argentina), DIGEMID (Peru), and ISP (Chile) all have different timelines, fee structures, and documentation expectations.

    For most US-headquartered MedTech sponsors running an FIH, the practical sweet spot is Colombia or Costa Rica for first-patient-in speed, with Brazil considered when the indication requires larger patient diversity or when the eventual commercial path runs through Latin America’s largest market.

    2. Are those countries easier because of recruitment, or because of ethics committees?

    Rocío came back with this follow-up — and it’s the right one to ask. The two drivers behave differently:

    • Recruitment speed is largely a function of investigator network density, hospital infrastructure, and patient population. It’s a relatively stable property of the country and the indication.
    • Ethics committee speed varies by which committee, not just which country. A Bogotá-based academic medical center’s CEI may turn around in 4–6 weeks; a regional committee might take 12. The same country can deliver dramatically different timelines depending on site selection.

    The implication for sponsors: pick countries where both the recruitment and the committee math work, then pick sites where you’ve already mapped CEI cycle times empirically. Don’t optimize one without the other.

    3. Will the FDA accept clinical data generated in Latin America?

    This question, from Bhavik Gondaliya (Germany, RA), is the one that gates every conversation about whether LatAm FIH data will actually contribute to a US regulatory submission. The short answer: yes, with conditions.

    The FDA’s longstanding position on foreign clinical data is codified in 21 CFR 814.15 for PMA submissions and in 21 CFR 812.28 (subpart B) for IDE and marketing submissions, and is described on FDA’s official page, Acceptance of Data from Clinical Investigations for Medical Devices (the 2018 guidance “Acceptance of Clinical Data to Support Medical Device Applications and Submissions”). LatAm data is acceptable if:

    • The study was conducted in accordance with Good Clinical Practice (GCP), including independent ethics review and informed consent
    • The data are applicable to the US patient population (the FDA looks for population overlap on the relevant clinical and demographic axes)
    • The site investigators were qualified, the protocol was scientifically sound, and the data are auditable by FDA inspectors

    For most early-stage MedTech sponsors, the practical playbook is to design the LatAm FIH so that its protocol, endpoints, and case report forms look like what an FDA reviewer would expect to see in a US pivotal study. Doing this work upfront makes the eventual bridging to a US IDE or 510(k)/De Novo dramatically smoother.

    4. How do you handle the ethics of providing investigational therapy “for free” in lower-resource settings?

    Nyerngoor Korda Hewitt (UK, Director of Regulatory Affairs and Quality) raised this — and it’s a question every sponsor should be ready for. The concern is real: when an FIH protocol provides expensive investigational therapy at no cost in a country where standard care is often unaffordable, you can create undue inducement.

    The frameworks that govern this are well-established — the Declaration of Helsinki (especially Articles 19–20 on vulnerable populations), the Council for International Organizations of Medical Sciences (CIOMS) International Ethical Guidelines, and country-specific implementations. Operationally, robust sponsors design their LatAm FIH protocols to address inducement directly:

    • Post-trial access — explicit commitments about whether participants will continue to receive the therapy after the trial ends, and under what conditions
    • Standard-of-care arms — when ethically and statistically appropriate, designing comparator arms so participants aren’t forced to choose between trial enrollment and accessible care
    • Independent ethics review in the host country, with documented review of the inducement question by the local CEI
    • Community engagement — particularly for indications where the trial may shape future access in the country

    The audience response on this question made clear: it’s a topic experienced sponsors and their RA teams take seriously, and one ethics committees in Colombia, Mexico, Chile, and elsewhere actively probe.

    5. Step-by-step: I have a de novo medical device and I want to do FIH in Panama or Bolivia. What does it actually look like?

    This question, from Joseph Skraba (University of Texas at Austin, Manager of Medical Device Commercialization), was the most operational of the session. Here’s the compressed playbook for a de novo Class II/III medical device sponsor:

    1. Pre-clinical foundation — bench testing, biocompatibility (ISO 10993), sterilization validation, and animal study data sufficient to support first human exposure. This is non-negotiable.
    2. FDA pre-submission (Q-Sub) is optional but strongly recommended — even for studies conducted entirely outside the US, a Q-Sub conversation aligns the FDA’s expectations for how the foreign data will support a future US submission. This is “free insurance” for your eventual regulatory path.
    3. Export approval — for a non-US-cleared device, you’ll need an FDA Export Certificate (typically a Certificate to Foreign Government, CFG) under Section 801(e) of the FD&C Act. Lead time is usually 4–6 weeks.
    4. In-country regulatory approval — country-specific medical device authorization. INVIMA (Colombia) and ANMAT (Argentina) have streamlined pathways for clinical investigation devices; smaller markets like Panama and Bolivia rely on Ministry of Health approvals that vary in predictability. Plan 8–16 weeks.
    5. Ethics committee review — single-site or multi-site CEI approval. Allow 4–12 weeks depending on country and committee. Many sponsors run this in parallel with regulatory.
    6. Site activation — investigator agreements, indemnification (and clinical trial insurance — required in most LatAm countries), training on the IFU and protocol, IRT/EDC system rollout.
    7. First-patient-in — typically 6–9 months from kickoff for a well-prepared sponsor, faster with an experienced in-country CRO.

    The realistic end-to-end timeline from contracting to first-patient-in is 6–9 months for sponsors who arrive prepared, longer for sponsors who try to compress pre-clinical or skip the FDA Q-Sub.

    Bonus: “Statistical power with 5 patients?”

    Stephanie Grassmann (Switzerland, MedTechXperts LLC) lobbed this one in — and the answer is: FIH studies aren’t powered for inferential statistics, and that’s by design.

    An FIH/early-feasibility study (typically 5–30 patients) is designed to evaluate safety, device handling, procedural success, and preliminary signals of efficacy. The endpoints are descriptive: rates, intervals, mean changes from baseline. The next study (pilot or pivotal, often 50–300+ patients) is where powered hypothesis testing begins. The two studies serve different scientific purposes and are evaluated by the FDA on different criteria.

    For sponsors evaluating whether their LatAm FIH will “count” toward their eventual US submission: it counts if it answers the questions a 5–30 patient study is designed to answer. Don’t try to make it carry weight it wasn’t designed to bear.

    Who was in the room

    The 98 attendees came from 17 countries across North America, Europe, Latin America, and Asia, with roles ranging from Regulatory Affairs leaders and Quality directors to MedTech founders and CEOs. The session ran from 11:00 AM to 12:02 PM ET on Friday, May 8, 2026, and 20% of listeners stayed for the final two minutes — an engagement signal that tracks with the seriousness of the questions asked.

    Next steps for your team

    If your team is actively planning a first-in-human study and wrestling with any of the questions above, here’s how to move forward:

    • Free 30-minute feasibility screen — share your indication, target patient count, and target FPI date, and we’ll tell you which 2–3 LatAm countries are realistic for your specific case. Book a call →
    • Read the case studies — bioaccess® has supported FIH and early-feasibility studies for cardiology, neurology, ophthalmology, and orthopedic device sponsors across Colombia, Mexico, Chile, Costa Rica, and Brazil. See recent case studies →
    • Stay current — we publish new analyses of LatAm regulatory shifts (ANVISA’s 2026–2027 international convergence agenda, FDA’s December 2025 RWE guidance and what it means for LatAm data, ophthalmic FIH dynamics in smaller markets) every week. Subscribe via the form below.

    Thanks to the 98 MedTech professionals who joined the session, and to the panelists and moderators who made the depth of the discussion possible. The next Friday In Focus session will be announced shortly.

  • Master Early Phase Clinical Trials in Colombia: Best Practices for Success

    Master Early Phase Clinical Trials in Colombia: Best Practices for Success

    Introduction

    For sponsors looking to make their mark in clinical research, understanding the complexities of early phase trials in Colombia is essential. With a regulatory framework that allows for swift approvals and the potential for diverse patient populations, Colombia stands out as a strategic hub for first-in-human studies. Yet, navigating these challenges requires careful planning and strategic foresight, particularly in areas like regulatory compliance and patient recruitment.

    How can sponsors tackle these challenges to ensure their trials not only start on the right foot but also deliver the best results? Addressing these challenges head-on is crucial for ensuring successful trial outcomes and maximizing the potential of this vibrant market.

    Understand Colombia’s Regulatory Landscape for Early Phase Trials

    Understanding Colombia’s regulatory landscape is crucial for sponsors aiming to conduct first-in-human studies efficiently. Colombia’s oversight framework for initial phase studies is primarily managed by the National Food and Drug Surveillance Institute (INVIMA). The approval process can be completed in as little as 60 to 90 days, a significant advantage over many other regions. Key requirements include:

    • Pre-Submission Consultation: Engaging with INVIMA early can clarify expectations and streamline the submission process, reducing potential delays.
    • Documentation: Crucial documents encompass the study protocol, informed consent forms, and investigator brochures. Ensuring these documents meet INVIMA’s standards is critical for approval.
    • Ethics Committee Approval: This must be obtained prior to submitting to INVIMA and can run concurrently with the regulatory submission, allowing for a more efficient timeline.

    By mastering these requirements, sponsors can dramatically enhance their chances of a successful initiation and capitalize on Colombia’s strategic benefits in speed and cost efficiency for early phase clinical trial Colombia.

    This flowchart outlines the steps sponsors need to take to navigate the regulatory landscape in Colombia. Each box represents a key requirement, and the arrows show the order in which these steps should be completed to ensure a smooth approval process.

    Optimize Site Selection and Activation for Efficient Trials

    Effective site selection is not just a step; it’s a cornerstone for the success of early phase clinical trial Colombia. To optimize this process, consider the following best practices:

    • Evaluate Site Capabilities: Thoroughly assess the infrastructure, staff qualifications, and prior trial experience of potential sites. This assessment ensures that chosen locations meet the requirements for first-in-human (FIH) studies, adhering to ICH-GCP standards and facilitating FDA-bridgeable data acceptance. Specific capabilities to consider include access to advanced medical technologies, skilled clinical staff, and a history of successful study management.
    • Diverse Patient Populations: Prioritize sites located in urban areas that provide access to diverse patient demographics. This approach not only enhances recruitment efforts but also boosts the generalizability of study outcomes, which is crucial for submission processes. As noted in a February 2026 study in Cureus, emerging regions like Latin America consistently outperform traditional markets in early phase clinical trial Colombia fundamentals, making diverse patient access a strategic advantage.
    • Streamlined Activation Processes: Working together with sites can really speed up the activation process, especially when they have established relationships with local regulatory authorities, such as INVIMA and COFEPRIS, and ethics committees. ‘bioaccess®’s Innovation Runway service is designed to facilitate this by providing a structured pathway that accelerates development for MedTech, Biopharma, and Radiopharma startups, enabling them to reach milestones 40% faster. The recent Proyecto de Ley 191 seeks to align Colombia’s approval speed with Argentina’s 62-day limit for studies, further enhancing the efficiency of the process.

    However, overlooking site capabilities or delaying engagement with regional oversight authorities can lead to significant setbacks. By addressing these challenges proactively, sponsors can not only avoid delays but also enhance the overall success of their research programs in Colombia.

    This mindmap starts with the main goal at the center and branches out into key practices. Each branch represents a best practice, and the sub-branches provide more details on what to consider for each practice. Follow the branches to understand how each aspect contributes to optimizing clinical trials.

    Leverage Local Expertise to Enhance Trial Success

    Maximizing the success of early phase clinical trial Colombia hinges on leveraging regional expertise. Here are key strategies to maximize this advantage:

    • Collaborate with Local CROs: Partnering with Contract Research Organizations (CROs) like bioaccess®, which possess in-depth knowledge of the Colombian regulatory landscape, including compliance with INVIMA guidelines and ICH-GCP standards, can drastically accelerate the approval process, achieving regulatory milestones in as little as 30 days through COFEPRIS’s streamlined pathway.
    • Engage Local Investigators: Local principal investigators (PIs) provide critical insights into effective patient recruitment strategies and cultural nuances that can improve participant engagement and retention. Their invaluable insights allow for tailored strategies, effectively engaging potential study participants and boosting recruitment rates. A regional principal investigator emphasized, ‘Understanding the community’s concerns and values is essential for building trust and encouraging participation in studies.’ This sentiment is reflected by bioaccess®’s leadership, who emphasize the significance of regional knowledge in bridging the gap between medical innovation and clinical research.
    • Engage Regional Networks: Building relationships with regional healthcare providers and patient advocacy organizations expands recruitment efforts and guarantees diverse representation among study participants. These networks can facilitate outreach and foster trust within the community, which is vital for successful enrollment. Bioaccess® has effectively expedited the progress of over 50 MedTech, Biopharma, and Radiopharma companies from concept to first-in-human studies, demonstrating the value of utilizing regional networks.

    By effectively utilizing these regional resources, sponsors can navigate the complexities of the Colombian research landscape, which is crucial for the early phase clinical trial Colombia, leading to enhanced outcomes and expedited timelines for first-in-human studies. Harnessing these regional resources not only simplifies the research process but also enhances the likelihood of successful outcomes.

    The center of the mindmap shows the main goal of enhancing trial success. Each branch represents a key strategy, and the sub-branches provide more details about how to implement these strategies. This layout helps you see how everything connects and the importance of local expertise in clinical trials.

    Implement Effective Patient Recruitment Strategies

    In Colombia, the success of early phase clinical trial Colombia hinges on effective patient recruitment. To optimize recruitment efforts, consider the following strategies:

    • Community Engagement: Establishing strong relationships with local communities is essential. Involving community leaders and organizations can assist in raising awareness about the study and its potential advantages, building trust and promoting participation. This method not only improves recruitment but also aligns with ethical standards set by INVIMA, ensuring that studies are conducted with community support.
    • Utilize Digital Platforms: Harness the power of social media and online patient registries to reach a broader audience. Digital outreach can significantly expand the recruitment pool, particularly among younger demographics who are more likely to engage with online content. This method can also enable faster communication and information distribution regarding the study.

    Many potential participants face obstacles that prevent them from enrolling in clinical studies. Implementing incentives like travel reimbursement and complimentary health screenings is crucial for encouraging potential participants to enroll in the study. These incentives can address barriers to participation, making it easier for individuals to commit to the study.

    By strategically implementing these targeted recruitment strategies, sponsors will enhance enrollment rates, ensuring that studies proceed on schedule while adhering to ICH-GCP standards and compliance requirements. Ultimately, these strategies not only streamline the recruitment process but also elevate the quality of clinical research outcomes.

    This mindmap shows the key strategies for recruiting patients in clinical trials. Start at the center with the main idea, then follow the branches to explore each strategy and its specific actions. Each color represents a different strategy, making it easy to see how they all connect.

    Conclusion

    Mastering early phase clinical trials in Colombia is not just an opportunity; it’s a strategic imperative for sponsors. Understanding the regulatory landscape is crucial. Optimizing site selection and activation, leveraging local expertise, and implementing effective patient recruitment strategies can significantly enhance success rates in this region known for speed and cost efficiency.

    Key insights discussed throughout the article highlight the importance of:

    1. Engaging with INVIMA early
    2. Selecting sites with diverse patient populations
    3. Collaborating with local CROs and investigators

    These strategies not only streamline the approval process but also ensure that studies are conducted in compliance with ICH-GCP standards, ultimately leading to more reliable outcomes. Additionally, fostering community engagement and utilizing digital platforms for recruitment can address barriers and enhance participant enrollment.

    These best practices are vital for success. As the landscape for early phase clinical trials continues to evolve, embracing the unique advantages that Colombia offers will empower sponsors to navigate complexities with confidence. This proactive approach not only accelerates timelines but also enhances the quality of clinical outcomes. Engaging with local expertise and communities is essential for achieving successful clinical outcomes and ensuring that research efforts align with the needs and values of the population.

    Frequently Asked Questions

    What is the primary regulatory authority overseeing early phase trials in Colombia?

    The primary regulatory authority overseeing early phase trials in Colombia is the National Food and Drug Surveillance Institute (INVIMA).

    What is the typical timeline for obtaining approval for first-in-human studies in Colombia?

    The approval process for first-in-human studies in Colombia can be completed in as little as 60 to 90 days, which is a significant advantage compared to many other regions.

    What is the importance of engaging with INVIMA early in the approval process?

    Engaging with INVIMA early through a Pre-Submission Consultation can clarify expectations and streamline the submission process, ultimately reducing potential delays.

    What key documents are required for submitting a clinical trial application to INVIMA?

    Key documents required include the study protocol, informed consent forms, and investigator brochures. These documents must meet INVIMA’s standards for approval.

    Is Ethics Committee Approval necessary before submitting to INVIMA?

    Yes, Ethics Committee Approval must be obtained prior to submitting to INVIMA. This approval can run concurrently with the regulatory submission, which aids in creating a more efficient timeline.

    How can sponsors enhance their chances of successful trial initiation in Colombia?

    By mastering the regulatory requirements and engaging with INVIMA early, sponsors can significantly enhance their chances of a successful initiation of early phase clinical trials in Colombia.

    What strategic advantages does Colombia offer for early phase clinical trials?

    Colombia offers strategic advantages such as speed in the approval process, cost efficiency, and favorable regulatory pathways for early phase clinical trials, making it an attractive location for MedTech, Biopharma, and Radiopharmaceutical companies.

    List of Sources

    1. Understand Colombia’s Regulatory Landscape for Early Phase Trials
      • medium.com (https://medium.com/@jmartinezclark/colombia-s-invima-requirements-for-pharma-clinical-trial-protocol-approval-bed968b6bab1)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/colombia)
    2. Optimize Site Selection and Activation for Efficient Trials
      • onlinelibrary.wiley.com (https://onlinelibrary.wiley.com/doi/10.1002/cam4.71099)
      • linkedin.com (https://linkedin.com/pulse/colombia-rewriting-its-clinical-trial-rules-rest-martinez-clark-w7hme)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/colombia)
    3. Leverage Local Expertise to Enhance Trial Success
      • cohortias.com (https://cohortias.com/clinical-trials-in-colombia)
      • pmc.ncbi.nlm.nih.gov (https://pmc.ncbi.nlm.nih.gov/articles/PMC12311479)
      • bioaccessla.com (https://bioaccessla.com/br/blog/achieve-50-faster-patient-enrollment-in-medtech-trials-in-colombia)
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/colombia)
      • Travel Nursing Jobs, Salary & Career Insights (https://whiteglovecare.com/healthcare-recruiter-tips-quotes)
    4. Implement Effective Patient Recruitment Strategies
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/colombia)
      • Patient Engagement Quotes: For Every Purpose & Audience (https://nclusiv.co.uk/edi-consulting/f/patient-engagement-quotes-for-every-purpose-audience)
      • Challenges and Opportunities for Cancer Clinical Trials Development in Latin America | JCO Global Oncology (https://ascopubs.org/doi/10.1200/GO-25-00383)

  • Best Practices for FIH Clinical Trials in Colombia: Key Strategies

    Best Practices for FIH Clinical Trials in Colombia: Key Strategies

    Introduction

    Navigating the regulatory landscape of first-in-human (FIH) clinical trials in Colombia can be daunting, yet it presents unique opportunities for sponsors in MedTech, Biopharma, and Radiopharmaceutical sectors. With the National Food and Drug Surveillance Institute (INVIMA) overseeing a regulatory framework that promises expedited approval timelines, understanding the nuances of compliance can significantly enhance trial success.

    So, how can sponsors effectively leverage:

    • Early feasibility studies
    • Patient recruitment strategies
    • Site selection

    to ensure their trials run smoothly and on time? Let’s explore some key strategies that can help streamline the regulatory process and position organizations at the forefront of clinical advancements in Colombia.

    Understand the Regulatory Landscape for FIH Trials in Colombia

    Navigating the regulatory landscape for FIH clinical trial Colombia can be a daunting task for sponsors, yet it holds the key to unlocking efficient research pathways. Colombia’s regulatory framework is primarily overseen by the National Food and Drug Surveillance Institute (INVIMA). Understanding INVIMA’s regulations is not just beneficial; it’s essential for sponsors aiming to navigate the FIH clinical trial Colombia successfully. The validation process typically spans 60 to 90 days, which is notably faster than many other regions. Key requirements for successful submissions include:

    • Submission of a Clinical Trial Protocol: This document must detail the study design, objectives, and methodology, providing a comprehensive overview of the trial.
    • Ethics Committee Approval: Prior to submission to INVIMA, studies must secure approval from a registered Institutional Review Board (IRB) or Ethics Committee, ensuring ethical standards are met.
    • Compliance with ICH-GCP: All studies must adhere to the International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, which are essential for maintaining the integrity and quality of clinical data.

    Mastering these regulations empowers organizations to streamline submissions and overcome common hurdles that often delay study initiation. Recent legislative changes, including Colombia’s Proyecto de Ley 191, aim to further enhance the efficiency of the approval process for FIH clinical trial Colombia, potentially reducing timelines and improving the overall landscape for these studies. Embracing these regulatory insights not only accelerates study initiation but also positions organizations at the forefront of clinical innovation in Colombia.

    This flowchart outlines the steps sponsors need to take to navigate the regulatory landscape for FIH clinical trials in Colombia. Each box represents a key action, and the arrows show the order in which these actions should be completed. Follow the flow to understand how to successfully initiate a clinical trial.

    Leverage Early Feasibility Studies to Enhance Trial Success

    Early feasibility studies (EFS) play a crucial role in the development of medical devices and pharmaceuticals, providing essential safety and efficacy data before advancing to larger trials. EFS in Colombia provides key advantages:

    • Regulatory Insights: EFS can uncover potential regulatory challenges early, allowing sponsors to make necessary adjustments prior to full-scale trials. bioaccess® assists in navigating the registration pathways with INVIMA, ANVISA, and COFEPRIS, ensuring compliance with local regulations and facilitating a streamlined approval process.
    • Cost Efficiency: By validating concepts at an early stage, sponsors can mitigate the risk of expensive late-stage failures, leading to significant resource savings. With bioaccess®, companies can achieve savings of approximately $25K per patient, significantly lowering overall study costs. The typical authorization timeline for clinical studies in Colombia is roughly 60 to 90 days, which is significantly quicker than in numerous other areas.
    • Patient Engagement: EFS typically involve smaller patient cohorts, allowing for closer interaction with participants and the collection of qualitative feedback that can inform further development. This method boosts data quality and speeds up patient recruitment, with bioaccess® facilitating faster enrollment processes.

    To fully leverage the benefits of EFS, sponsors should design studies that are robust and compliant with regulatory expectations, ensuring clear endpoints and methodologies that meet INVIMA’s standards. By leveraging bioaccess®’s expertise, sponsors can significantly enhance their chances of successful study outcomes and regulatory compliance.

    This mindmap illustrates the key benefits of early feasibility studies. Start at the center with EFS, then explore each branch to see how regulatory insights, cost efficiency, and patient engagement contribute to successful trials.

    Implement Effective Patient Recruitment Strategies for Timely Trials

    Patient recruitment is often the bottleneck in first-in-human (FIH) studies, leading to costly delays that can jeopardize research success. In Colombia, sponsors can adopt several effective strategies to enhance recruitment efforts:

    • Utilize Local Networks: Collaborating with local healthcare providers and community organizations is essential for identifying potential participants who meet eligibility criteria. Engaging with these networks can facilitate trust and improve participant willingness to enroll.
    • Culturally Tailored Communication: Developing recruitment materials in Spanish and considering cultural sensitivities can significantly enhance engagement. Clear, transparent communication about study objectives and participant expectations fosters trust and encourages participation.
    • Leverage Digital Platforms: Utilizing social media and online patient registries broadens outreach and attracts a diverse patient population. Digital tools can enhance the recruitment process, facilitating connections with potential participants and keeping them informed about study opportunities.

    By implementing these strategies, sponsors can transform recruitment efforts, paving the way for timely and successful FIH clinical trials in Colombia that meet both participant needs and regulatory standards. This proactive approach not only enhances participant engagement but also aligns with regulatory requirements set forth by INVIMA, ensuring compliance with ICH-GCP standards and facilitating a smoother pathway to regulatory approval.

    This mindmap shows the main strategies for recruiting patients in clinical trials. Each branch represents a different strategy, and the sub-branches provide specific actions to take. Follow the branches to see how each strategy contributes to successful recruitment.

    Optimize Site Selection and Activation for Efficient Trial Execution

    In the competitive landscape of clinical research, the choice and timely activation of investigation sites are pivotal for the success of the FIH clinical trial Colombia. Sponsors should adopt the following best practices:

    • Evaluate Site Experience: Prioritize sites with a strong history of conducting FIH trials and a thorough understanding of INVIMA regulations. This ensures compliance and enhances operational efficiency, critical for meeting regulatory standards.
    • Assess Patient Demographics: Choose sites strategically located in regions with a high prevalence of the target patient population. This method enhances recruitment and speeds up patient enrollment, which is crucial for maintaining study timelines.
    • Streamline Activation Processes: Initiate site activation as early as possible in the planning phase. Ensure that all essential documentation, including compliance clearances and site agreements, are in place to prevent delays. Taking this proactive approach can really cut down the time it takes to go from site selection to getting patients enrolled.

    By optimizing site selection and activation processes, sponsors not only enhance efficiency but also significantly improve their chances of achieving successful study results. Ultimately, a strategic approach to site selection and activation can be the difference between success and failure in clinical trials.

    This flowchart outlines the key steps to optimize site selection and activation in clinical trials. Follow the arrows to see how each practice connects and contributes to the overall efficiency of the trial process.

    Integrate U.S. Regulatory Standards with Latin American Execution for Faster Approvals

    Navigating the complexities of compliance in Colombia can be daunting, but aligning U.S. standards with local strategies can streamline the approval process for first-in-human studies. Here are key strategies sponsors can adopt:

    • Align Study Designs with FDA Expectations: Ensure that clinical trial designs adhere to FDA requirements, as this alignment can facilitate smoother submissions and acceptance of data from Colombian trials. This encompasses following ICH-GCP standards, which are essential for compliance with regulations.
    • Utilize Local Expertise: Engage with local CROs like bioaccess®, which specialize in navigating both U.S. and Colombian compliance landscapes. Their expertise ensures compliance with INVIMA (Instituto Nacional de Vigilancia de Medicamentos y Alimentos) regulations, enhancing operational efficiency and reducing the risk of delays.
    • Utilize Fast-Track Pathways: Capitalize on Colombia’s accelerated pathways, which can shorten timelines by up to 40% compared to conventional routes. By employing these pathways, organizations can attain regulatory clearance in as little as 30 days, significantly speeding up the clinical development process. bioaccess®’s Innovation Runway is designed to further accelerate clinical development for MedTech, Biopharma, and Radiopharma startups, helping them reach clinical milestones faster.

    By leveraging local expertise, sponsors can navigate these complexities more effectively, ensuring a smoother approval process. Embracing these strategies not only accelerates approvals but also positions sponsors for success in the competitive Colombian market.

    This flowchart outlines the key strategies for speeding up clinical trial approvals in Colombia. Each branch represents a strategy that can help sponsors navigate regulatory complexities and achieve quicker results.

    Conclusion

    Navigating the regulatory landscape for first-in-human (FIH) clinical trials in Colombia presents significant challenges that sponsors must overcome. This article has shared key strategies that can help sponsors streamline the approval process and improve trial outcomes. Organizations can significantly improve their chances of success by:

    1. Mastering INVIMA regulations
    2. Leveraging early feasibility studies
    3. Implementing effective patient recruitment strategies
    4. Optimizing site selection
    5. Integrating U.S. regulatory standards

    Key arguments presented emphasize the importance of early regulatory insights, cost efficiency, and patient engagement, all of which contribute to the overall effectiveness of clinical trials. The value of collaborating with local expertise and utilizing innovative pathways to expedite approvals cannot be overstated, as these factors lead to a more efficient trial process. By adopting these best practices, sponsors can navigate the complexities of FIH trials in Colombia and position themselves for clinical success.

    The message is straightforward: a strategic approach to FIH clinical trials in Colombia can speed up timelines, cut costs, and improve research quality. As the landscape of clinical development continues to evolve, sponsors are encouraged to leverage these insights and best practices to drive innovation and enhance patient care in the region. By doing so, they will not only contribute to the advancement of medical science but also establish a strong foothold in the dynamic Latin American market.

    Frequently Asked Questions

    What is the primary regulatory authority overseeing FIH clinical trials in Colombia?

    The primary regulatory authority overseeing FIH clinical trials in Colombia is the National Food and Drug Surveillance Institute (INVIMA).

    What is the typical validation process timeline for FIH clinical trials in Colombia?

    The typical validation process for FIH clinical trials in Colombia spans 60 to 90 days, which is faster than many other regions.

    What are the key requirements for submitting a clinical trial protocol to INVIMA?

    Key requirements for submitting a clinical trial protocol to INVIMA include the submission of a detailed Clinical Trial Protocol, obtaining Ethics Committee Approval from a registered Institutional Review Board (IRB) or Ethics Committee, and compliance with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards.

    How can recent legislative changes, such as Proyecto de Ley 191, impact FIH clinical trials in Colombia?

    Recent legislative changes, including Proyecto de Ley 191, aim to enhance the efficiency of the approval process for FIH clinical trials in Colombia, potentially reducing timelines and improving the overall landscape for these studies.

    What advantages do early feasibility studies (EFS) provide in the context of clinical trials in Colombia?

    Early feasibility studies (EFS) provide several advantages, including uncovering potential regulatory challenges early, cost efficiency by validating concepts at an early stage, and enhanced patient engagement through smaller cohorts that allow for closer interaction and qualitative feedback.

    How does bioaccess® assist sponsors in navigating the regulatory pathways for clinical trials?

    bioaccess® assists sponsors by navigating the registration pathways with INVIMA, ANVISA, and COFEPRIS, ensuring compliance with local regulations and facilitating a streamlined approval process.

    What is the typical authorization timeline for clinical studies in Colombia?

    The typical authorization timeline for clinical studies in Colombia is approximately 60 to 90 days, which is significantly quicker than in many other areas.

    How can sponsors enhance their chances of successful study outcomes in Colombia?

    Sponsors can enhance their chances of successful study outcomes by designing robust studies that comply with regulatory expectations, ensuring clear endpoints and methodologies that meet INVIMA’s standards, and leveraging bioaccess®’s expertise.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Colombia
      • linkedin.com (https://linkedin.com/pulse/colombia-rewriting-its-clinical-trial-rules-rest-martinez-clark-w7hme)
      • Latin America the ‘Hidden Gem’ for First-in-Human Medical Device Trials (https://clinicalresearchnewsonline.com/news/2025/08/14/latin-america-the-hidden-gem-for-first-in-human-medical-device-trials)
    2. Leverage Early Feasibility Studies to Enhance Trial Success
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
      • meddeviceonline.com (https://meddeviceonline.com/doc/colombia-a-strategic-choice-for-medtech-clinical-trials-0001)
      • Quotes About Medical Research (https://changingthepresent.org/pages/quotes-about-medical-research)
    3. Implement Effective Patient Recruitment Strategies for Timely Trials
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Clinical studies: the challenge of patient recruitment (https://servier.com/en/newsroom/clinical-studies-patient-recruitment)
      • Enrollment in Clinical Trials: Statistics and Patient Recruitment Strategies | Power (https://withpower.com/guides/enrollment-in-clinical-trials-statistics-and-patient-recruitment-strategies)
      • What clinical trial statistics tell us about the state of research today (https://antidote.me/blog/what-clinical-trial-statistics-tell-us-about-the-state-of-research-today)
      • Seven Best Practices For Clinical Trial Patient Recruitment (https://openclinica.com/blog/seven-patient-recruitment-best-practices-used-by-leading-research-studies)
    4. Optimize Site Selection and Activation for Efficient Trial Execution
      • biobostonconsulting.com (https://biobostonconsulting.com/top-5-alarming-statistics-you-must-know-about-clinical-trial-site-selection)
      • Optimizing Site Selection and Management for Clinical Trial Success (https://studypages.com/blog/optimizing-site-selection-and-management-for-clinical-trial-success)
      • cryosite.com (https://cryosite.com/conducting-site-selection-the-key-factors-and-strategies-in-site-selection-for-clinical-trials)
      • Clinical Trial Site Selection: Key Factors & Best Practices | IntuitionLabs (https://intuitionlabs.ai/articles/clinical-trial-site-selection)
      • Strategies for Successful Site Selection in Clinical Trials (https://advarra.com/blog/strategies-for-successful-site-selection-in-clinical-trials)
    5. Integrate U.S. Regulatory Standards with Latin American Execution for Faster Approvals
      • Clinical trial timelines in flux: Considerations for U.S. and UK biopharma companies (https://rsmus.com/insights/industries/life-sciences/clinical-trial-timelines-in-flux.html)
      • ccrps.org (https://ccrps.org/clinical-research-blog/the-impact-of-regulatory-changes-on-clinical-trials-2025-analysis)
      • truveta.com (https://truveta.com/blog/news/fda-real-world-evidence-transparency)

  • Conducting a First-in-Human Clinical Trial in Colombia: A Step-by-Step Guide

    Conducting a First-in-Human Clinical Trial in Colombia: A Step-by-Step Guide

    Introduction

    In Colombia, the path to successful first-in-human (FIH) clinical trials is fraught with regulatory challenges that demand careful navigation. This guide aims to equip researchers and organizations with the insights needed to navigate these trials effectively, detailing essential steps from regulatory compliance to patient recruitment strategies. Navigating these complexities can lead to significant setbacks if not managed properly. To overcome these challenges, trial sponsors must adopt strategic approaches that leverage local insights.

    Understand the Regulatory Landscape for FIH Trials in Colombia

    To navigate the complexities of conducting a first-in-human clinical trial in Colombia, a thorough understanding of the regulatory framework is crucial. The Instituto Nacional de Vigilancia de Medicamentos y Alimentos oversees this framework, and here are the key steps to follow:

    1. Get Acquainted with Regulatory Guidelines: Review the latest guidelines from the regulatory authority, particularly Resolution 2378/2008, which outlines the requirements for research studies. This includes understanding the types of studies that require approval and the specific documentation needed.
    2. Approval Timelines: The regulatory authority typically assesses clinical study applications within 60 to 90 days. Delays can occur if submissions are incomplete or trials are complex. Significantly, the fast-track rare disease pathway has allowed companies such as Unravel Biosciences to initiate patient dosing in less than 90 days, showcasing the effectiveness of expedited processes in the region.
    3. Documentation Requirements: Prepare essential documents such as the Clinical Trial Protocol, Informed Consent Forms, Investigator’s Brochure, and any preclinical data that supports the safety and efficacy of the investigational product.
    4. Ethics Committee Approval: Before submitting to INVIMA, obtain approval from a local ethics committee. Expect this process to take about 30 to 45 days, depending on how the committee is scheduled.
    5. Adherence to ICH-GCP: Ensure that your study complies with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, as this is a requirement for acceptance by authorities and enhances the credibility of your data.

    Have you considered how submission completeness and trial complexity might affect your approval timeline? By comprehending these compliance aspects, you can optimize the approval process and reduce potential delays in the first-in-human clinical trial in Colombia. By leveraging Colombia’s regulatory framework, you can not only streamline your approval process but also enhance the likelihood of your study’s success in a competitive landscape.

    This flowchart outlines the steps you need to follow for conducting a first-in-human clinical trial in Colombia. Each box represents a key step, and the arrows show the order in which you should complete them. Following this path will help you navigate the regulatory landscape effectively.

    Prepare Essential Preclinical Data and Documentation

    Meticulous preparation of preclinical data is non-negotiable before embarking on a first-in-human clinical trial in Colombia. Follow these essential steps to ensure a successful process:

    1. Conduct Preclinical Studies: Complete necessary preclinical studies, including pharmacology, toxicology, and pharmacokinetics. These studies must demonstrate the safety and biological activity of the investigational product, providing a solid foundation for human evaluations.

    2. Compile a Preclinical Dossier: Create a detailed dossier that includes:

      • A summary of preclinical studies
      • Results from animal studies, including dosing and toxicity data
      • Justification for the proposed starting dose in humans
      • Relevant manufacturing information that supports product quality.

    3. Prepare the Clinical Study Protocol: Draft a clear and concise clinical study protocol outlining the study design, objectives, methodology, and statistical analysis plan. This document is crucial for regulatory submission to the relevant authorities and operational execution.

    4. Informed Consent Forms: Develop informed consent forms that clearly explain the trial’s purpose, procedures, risks, and benefits to potential participants. These forms must receive approval from the ethics committee before submission to INVIMA.

    5. Investigator’s Brochure: Create an Investigator’s Brochure that offers detailed information about the investigational product, including its pharmacological properties, safety profile, and any prior trial data.

    Thorough preparation of these documents not only boosts your approval odds but also paves the way for a seamless transition into the research phase. In Colombia, where regulatory pathways are efficient, prompt submission and compliance with ICH-GCP standards can greatly expedite the study process, positioning it as a prime location for the first-in-human clinical trial in Colombia.

    Each box represents a crucial step in preparing for a clinical trial. Follow the arrows to see how each step leads to the next, ensuring all necessary documentation is completed before moving forward.

    Execute the Trial: Site Selection, Recruitment, and Monitoring

    Conducting a first-in-human clinical trial in Colombia presents unique challenges that demand meticulous planning and oversight. Here’s how to effectively execute your trial:

    1. Site Selection: Choose clinical study sites that are experienced and equipped to conduct FIH studies. Consider factors such as:

      • Proximity to patient populations, which enhances recruitment potential.
      • Availability of trained staff familiar with FIH protocols.
      • Prior experience with similar studies, ensuring a smoother execution.
      • Compliance with ICH-GCP and INVIMA regulations, as well as the COFEPRIS 30-day approval pathway for medical devices, to meet local standards.

    2. Patient Recruitment: Develop a robust patient recruitment strategy that includes:

      • Engaging with local healthcare providers to identify potential participants, leveraging their networks for referrals.
      • Utilizing digital marketing and social media to reach a broader audience, as nearly 50% of potential participants learn about clinical studies through these channels.
      • Providing clear details about the study’s advantages and risks to promote participation, which can reduce financial anxiety and improve engagement.
      • Consider implementing virtual pre-screening visits. This approach removes barriers to enrollment and allows potential participants to assess their eligibility without the need to travel.

    3. Monitoring and Data Collection: Implement a comprehensive monitoring plan to ensure compliance with the protocol and regulatory requirements. This includes:

      • Regular site visits to assess adherence to the protocol and ICH-GCP standards, which can help mitigate dropout rates that affect trial integrity.
      • Training site staff on data collection procedures and reporting requirements to ensure accuracy and reliability.
      • Utilizing electronic data capture systems to streamline data collection and enhance accuracy, facilitating real-time monitoring of study progress.

    4. Safety Monitoring: Establish a safety monitoring plan that includes:

      • Regular review of adverse events and serious adverse events to ensure participant safety.
      • Communication with the ethics committee and INVIMA regarding any safety concerns, maintaining transparency and adherence to compliance expectations.

    By efficiently overseeing these operational elements, you enhance the quality of your study and ensure compliance with standards. This approach leads to successful outcomes in the fast-paced realm of first-in-human clinical trial in Colombia. Furthermore, utilizing bioaccess®’s Innovation Runway can expedite your development process, aiding you in achieving essential milestones more swiftly and securing funding before your runway expires.

    This flowchart illustrates the steps involved in executing a clinical trial. Each box represents a key area of focus, and the arrows show how these areas connect and flow into one another. Follow the arrows to understand the sequence of actions needed for a successful trial.

    Analyze Data and Submit Regulatory Findings

    Navigating the regulatory landscape after a first-in-human clinical trial in Colombia is crucial for ensuring the success of your investigational product. Here’s a structured approach to ensure compliance and enhance the credibility of your submission:

    1. Data Analysis: Conduct a comprehensive analysis of the collected data, emphasizing:

      • Safety and efficacy outcomes, ensuring all adverse events are documented.
      • Statistical significance of the results, utilizing appropriate statistical methods to validate findings.
      • Any unexpected findings that may influence the overall assessment of the investigational product, which should be clearly articulated in the report.

    2. Prepare the Clinical Study Report (CSR): Draft a detailed CSR that adheres to INVIMA’s requirements, including:

      • Study Objectives and Design: Clearly outline the purpose of the trial and the methodology employed.
      • Methodology and Statistical Analysis: Describe the study design, including participant selection, intervention details, and statistical methods used for analysis.
      • Results and Discussion: Present the findings in a clear format, supported by tables and figures, and discuss their implications in the context of existing literature.
      • Conclusions and Recommendations: Summarize the key findings and suggest directions for future research, including potential modifications for subsequent trials.

    3. Regulatory Submission: Submit the CSR along with any additional required documents to INVIMA, ensuring:

      • All documents are formatted according to INVIMA guidelines, which include specific sections mandated by the ICH-GCP standards.
      • Inclusion of supplementary data that supports your findings, such as safety reports and patient feedback, which can enhance the robustness of your submission.

    4. Follow-Up with INVIMA: After submission, maintain open communication with INVIMA to address any inquiries or requests for further information. Staying engaged with INVIMA not only helps address any questions but also shows your dedication to meeting regulatory standards.

    5. Prepare for Future Studies: Leverage insights gained from the study to inform the design of subsequent research, whether they involve larger patient populations or different investigational products. This iterative method not only enhances study design but also increases the chances of approval success.

    By meticulously analyzing your data and effectively communicating your findings through a well-structured CSR, you can significantly bolster the credibility of your trial and support future regulatory submissions, ultimately accelerating the path to market for your investigational product.

    This flowchart guides you through the steps needed after a clinical trial. Each box represents a key stage in the process, and the arrows show the order in which you should complete them. Follow the steps to ensure your submission is thorough and compliant!

    Conclusion

    Conducting a first-in-human clinical trial in Colombia presents unique challenges and opportunities that demand a strategic approach. Understanding the essential steps – like navigating INVIMA guidelines and ensuring compliance with ICH-GCP standards – allows researchers to optimize their trial processes and boost their chances of success. Colombia’s efficient regulatory pathways and supportive environment for clinical research make it a strategic choice for early-stage trials, particularly in the MedTech and biopharma sectors. However, navigating these pathways requires careful planning and adherence to regulations.

    Key arguments highlighted in this guide include the importance of thorough documentation preparation, such as preclinical data and informed consent forms, as well as the necessity of selecting appropriate trial sites and developing effective patient recruitment strategies. Every step, from choosing the right sites to analyzing data, is vital for meeting regulatory requirements and ensuring participant safety and data integrity. Engaging with local ethics committees and maintaining open communication with INVIMA further solidifies the credibility of the research.

    As the landscape for clinical trials continues to evolve, this evolving landscape offers both opportunities and challenges for researchers looking to bring innovative products to market. Stakeholders are encouraged to adopt best practices outlined in this guide, ensuring that they remain compliant while fostering innovation. By strategically navigating these complexities, organizations can not only enhance their trial outcomes but also play a pivotal role in advancing medical innovation in Colombia.

    Frequently Asked Questions

    What is the role of the Instituto Nacional de Vigilancia de Medicamentos y Alimentos (INVIMA) in FIH trials in Colombia?

    INVIMA oversees the regulatory framework for conducting first-in-human (FIH) clinical trials in Colombia, ensuring compliance with established guidelines and requirements.

    What are the key regulatory guidelines to review for conducting FIH trials in Colombia?

    It is essential to review the latest guidelines from INVIMA, particularly Resolution 2378/2008, which outlines the requirements for research studies, including the types of studies that need approval and the specific documentation required.

    What is the typical approval timeline for clinical study applications in Colombia?

    The regulatory authority typically assesses clinical study applications within 60 to 90 days. However, delays may occur if submissions are incomplete or if the trials are complex.

    What documentation is required for submitting an FIH trial in Colombia?

    Essential documents include the Clinical Trial Protocol, Informed Consent Forms, Investigator’s Brochure, and any preclinical data supporting the safety and efficacy of the investigational product.

    Is ethics committee approval necessary before submitting to INVIMA?

    Yes, approval from a local ethics committee is required prior to submission to INVIMA. This process usually takes about 30 to 45 days, depending on the committee’s scheduling.

    What standards must be adhered to for FIH trials in Colombia?

    Studies must comply with International Council for Harmonisation – Good Clinical Practice (ICH-GCP) standards, as this is a requirement for acceptance by authorities and enhances the credibility of the data.

    How can submission completeness and trial complexity affect the approval timeline?

    Incomplete submissions or complex trials can lead to delays in the approval process. Understanding these compliance aspects can help optimize the approval timeline and reduce potential delays.

    What advantages does Colombia offer for early-stage clinical trials?

    Colombia offers advantages such as expedited approval processes, cost efficiency, and access to a diverse patient population, making it a strategic location for early-stage clinical trials in Latin America.

    List of Sources

    1. Understand the Regulatory Landscape for FIH Trials in Colombia
      • linkedin.com (https://linkedin.com/pulse/colombia-rewriting-its-clinical-trial-rules-rest-martinez-clark-w7hme)
      • alzforum.org (https://alzforum.org/news/conference-coverage/nih-director-announces-100m-prevention-trial-genentech-antibody)
    2. Prepare Essential Preclinical Data and Documentation
      • Beyond the Safety Check: Why First-in-Human Trials Demand a New Approach in 2026 | BioPharm International (https://biopharminternational.com/view/safety-first-human-trials-new-approach)
      • First-in-Human Trial Participants: Not a Vulnerable Population, but Vulnerable Nonetheless – PMC (https://pmc.ncbi.nlm.nih.gov/articles/PMC2692671)
      • finance.yahoo.com (https://finance.yahoo.com/news/wave-life-sciences-announced-positive-201500678.html)
    3. Execute the Trial: Site Selection, Recruitment, and Monitoring
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
      • veristat.com (https://veristat.com/patient-recruitment-for-clinical-trials)
      • globenewswire.com (https://globenewswire.com/news-release/2026/01/22/3223958/0/en/clinical-trial-patient-recruitment-services-market-report-2026-2032-how-digital-and-physician-engagements-are-transforming-participant-enrollment.html)
      • gcihealth.com (https://gcihealth.com/2026/01/22/precision-relevance-and-prediction-the-future-of-clinical-trial-recruitment)
      • Strategies for Successful Site Selection in Clinical Trials (https://advarra.com/blog/strategies-for-successful-site-selection-in-clinical-trials)
    4. Analyze Data and Submit Regulatory Findings
      • linkedin.com (https://linkedin.com/pulse/clinical-study-reports-drug-development-comprehensive-hiep-ben–gensc)
      • Clinical Study Reports : Types and Use Cases (https://precisionformedicine.com/blog/clinical-study-reports-csr-types-and-use-cases)
      • easyglobaltraining.com (https://easyglobaltraining.com/blogs/what-fda-reviewers-really-look-for-in-a-clinical-study-report?srsltid=AfmBOoqW3j3I4W2ieOgE8cBS8usmL0z1vM6CeCNfbtY5HrqrQjaloqN1)
      • biopharmaservices.com (https://biopharmaservices.com/blog/bioequivalence-clinical-study-report-development-of-generic-products)

  • Ophthalmic First-In-Human Studies In Latin America: Why Smaller Markets Often Move Fastest

    Ophthalmic First-in-Human Studies in Latin America: Why Smaller Markets Often Move Fastest

    For ophthalmic medical device founders running their first-in-human (FIH) program — intravitreal injectors, glaucoma microshunts, retinal delivery platforms, intraocular lens innovations — the conventional wisdom says you go to a country with the largest patient pool and the most prestigious eye institutes. In Latin America, that usually points sponsors toward Mexico or Brazil first.

    That instinct is right for pivotal studies. For an FIH or early-feasibility study with 5 to 15 patients, however, our operational experience consistently shows a different pattern: smaller markets like El Salvador, Panama, and the Dominican Republic often deliver a faster path to first patient in. Here is why, and how to think about country selection for an ophthalmic FIH program.

    The FIH Math Is Different from the Pivotal Math

    Pivotal studies select for patient pool depth, statistical power, and reimbursement signal. FIH studies select for something else entirely: speed to first dose, regulatory predictability, and quality of investigator engagement on a small handful of patients.

    For a 10-patient ophthalmic FIH study, the binding constraint is rarely “are there enough eligible patients in the country” — almost any LATAM country has thousands of glaucoma, AMD, or refractive candidates. The binding constraints are:

    • Time from sponsor decision to first ethics committee submission
    • Time from EC approval to first patient screened
    • Investigator focus and availability across the dosing window
    • Regulatory predictability for a novel device class

    On all four, smaller markets often outperform the regional giants for FIH-stage work.

    Why Smaller Markets Move Faster on Ophthalmic FIH

    Three structural factors explain it.

    1. Lighter EC and regulatory queues. An ethics committee at a leading eye hospital in El Salvador or Panama might review three to six device protocols per quarter. The equivalent committee at a top São Paulo or Mexico City institute might be working through 30 to 60. Both are competent and rigorous; one simply has more capacity for a fast-track FIH protocol.

    2. Concentrated investigator attention. In smaller markets, a leading ophthalmologist running an FIH study is not splitting attention across 12 simultaneous trials. The principal investigator has direct line of sight on every screening visit, every dosing event, every follow-up — the kind of operational intimacy that materially reduces protocol deviations and data queries on a small-N study.

    3. Tighter sponsor-to-site communication. Smaller hospital systems mean fewer layers between sponsor, CRO, principal investigator, and ethics coordinator. A protocol clarification that takes a week to circulate at a large academic center can be resolved in a 30-minute call in a smaller setting.

    What This Looks Like in Practice for an Ophthalmic FIH

    For an intravitreal device, glaucoma microshunt, or refractive implant FIH program, a well-structured small-market approach typically looks like this:

    • Single-country FIH (5–10 patients). Concentrate enrollment at one or two specialized eye centers in a smaller market. Optimize for speed and data quality, not geographic diversity.
    • Validated translation and regulatory packets ready before EC submission. Smaller markets are fast on substance but unforgiving on document inconsistency.
    • Compressed feasibility-to-FPI window. A 6 to 8 week target from sponsor go-decision to first patient enrolled is achievable when site, EC, and country regulator are aligned from day one.
    • Clean handoff to a multi-country pivotal. Once FIH safety data is in hand, the pivotal can move to Mexico, Brazil, Argentina, or a multi-country footprint with the FIH evidence already supporting site selection conversations.

    When the Conventional Path Still Wins

    Smaller markets are not the right choice for every ophthalmic FIH. Three situations argue for going to Mexico or Brazil first:

    • Genetic ophthalmic indications where a specific sub-population is concentrated in one large country.
    • Complex imaging endpoints requiring a specific OCT, ultra-widefield imaging, or AI-assisted analysis platform that is only operational at a handful of large academic centers in the region.
    • Founder-led key opinion leader strategy where the FIH publication-to-investor narrative depends on a specific principal investigator’s involvement.

    For most early-stage ophthalmic device sponsors, however, the speed advantage of smaller markets at the FIH stage translates directly into reduced cash burn during the most capital-fragile window of the company’s life. In an industry where 90% of MedTech startups fail because they run out of capital before generating clinical evidence, that compression matters.

    Frequently Asked Questions

    How quickly can a well-designed ophthalmic FIH actually start in a smaller LATAM market?
    With prepared documents, an experienced site, and a clear regulatory pathway, 6 to 10 weeks from contract signature to first patient screened is realistic. The variability comes from how prepared the sponsor’s regulatory packet is, not from the country’s regulatory speed.

    Will FDA accept FIH data from El Salvador, Panama, or the Dominican Republic?
    Yes, under 21 CFR 812.28, provided the study is conducted in compliance with ICH-GCP. The FDA does not maintain a country whitelist; it evaluates each study on the quality of its execution, documentation, and ethics oversight.

    Should we run the FIH in a smaller market and then move the pivotal to Brazil or Mexico?
    This is a common and effective sequencing strategy for ophthalmic device programs. Smaller markets optimize for speed at the FIH stage. Larger markets optimize for enrollment depth, infrastructure, and regulatory signal at the pivotal stage. Designing the FIH protocol with the eventual pivotal in mind — same imaging modalities, same primary endpoint definitions, same data capture standards — makes the transition seamless.

    bioaccess® is the world’s only contract research organization built exclusively for first-in-human medical device trials, operating across 10 Latin American countries. Explore the FIH playbook at bioaccessla.com or estimate a study at bioaccessla.com/clinical-trial-calculator.

  • 4 Best Practices for First in Human Biopharma Trials in Chile

    4 Best Practices for First in Human Biopharma Trials in Chile

    Introduction

    While Chile’s regulatory framework offers promising approval timelines for first-in-human biopharma trials, the path to success is fraught with challenges that sponsors must navigate. As a strategic hub for clinical research in Latin America, Chile presents significant opportunities. Yet, the complexities of compliance, patient recruitment, and site selection present significant hurdles that can hinder progress.

    What strategies can sponsors implement to not only leverage Chile’s advantages but also navigate these obstacles for successful trial outcomes?

    Understand Regulatory Frameworks for FIH Trials in Chile

    Understanding the regulatory landscape for first in human biopharma Chile is crucial for sponsors aiming to expedite their clinical research efforts. Conducting FIH studies requires a thorough understanding of the frameworks established by the Instituto de Salud Pública (ISP) and strict adherence to ICH-GCP standards. The approval process is efficient, typically taking around 30 business days, positioning Chile as an attractive destination for sponsors seeking expedited timelines.

    Key regulations include:

    However, many sponsors find the regulatory landscape daunting due to its complexity and the need for meticulous preparation. To navigate this landscape effectively, sponsors need to prepare a detailed Clinical Trial Application (CTA). This should include:

    • Thorough study protocols
    • Patient safety measures
    • Robust data management plans

    Acquaintance with these guidelines not only simplifies the approval process but also enhances the credibility of study data, which is crucial for subsequent submissions to authorities such as the FDA. As of 2024, Chile ranks fourth among Latin American nations for research studies, highlighting its growing importance. This shift in research activity underscores the need for sponsors to act swiftly and strategically to capitalize on Chile’s favorable conditions for successful first in human biopharma Chile studies.

    This flowchart guides you through the steps needed to navigate the regulatory landscape for FIH trials in Chile. Start with understanding the regulations, then prepare your application, and follow through to the approval process. Each box represents a key step, and the arrows show how they connect.

    Conduct Early Feasibility Studies to Validate Trial Designs

    Early feasibility studies (EFS) are not just a formality; they are essential for validating study designs and ensuring project success in clinical research. In Chile, EFS offers vital insights into patient safety and device functionality, contributing to the advances of first in human biopharma Chile. These insights are crucial for navigating the complex compliance landscape. Typically involving a small cohort of participants – often ten or fewer – EFS focus on gathering initial data that can inform larger trials.

    To really make EFS work, sponsors need to connect with local clinical experts who know the ins and outs of compliance, including adherence to ICH-GCP standards and the requirements set forth by local authorities like the Instituto de Salud Pública (ISP). Utilizing feedback from participants during these studies is also essential, as it aids in refining protocols and improving the overall quality of the data gathered.

    Additionally, leveraging Chile’s diverse population can greatly enhance the generalizability of findings, making the data more reliable for future submissions. The streamlined regulatory pathways in Latin America, along with the capacity to obtain regulatory approval in as few as 4-8 weeks, position EFS as a strategic asset for early-stage trials, particularly as the first in human biopharma Chile. Moreover, sponsors can realize significant cost savings, estimated at $25K per individual, which can be reinvested into research and development or future funding milestones. By leveraging EFS effectively, sponsors can not only enhance their study designs but also secure a competitive edge in the clinical research landscape.

    This flowchart illustrates the steps involved in conducting Early Feasibility Studies. Each box represents a key action in the process, and the arrows show how these actions connect to achieve successful clinical trials.

    Implement Targeted Patient Recruitment Strategies

    Effective recruitment of participants is not just important; it’s essential for the success of first in human biopharma Chile studies. Sponsors should implement targeted strategies that resonate with the local population, including engaging community health organizations and local healthcare providers. Utilizing social media platforms for outreach can significantly enhance visibility and participation. Offering incentives for participation, such as financial compensation for time and travel, can further motivate potential participants. Additionally, ensuring that recruitment materials are culturally sensitive and accessible is crucial for maximizing enrollment rates.

    Patient registries and databases can help identify individuals who meet study criteria. This enhances the recruitment process. In Chile, where 37% of study centers fail to meet their recruitment targets, these strategies are vital for achieving enrollment goals. Without effective recruitment, studies may face delays or fail altogether. Furthermore, the integration of bilingual U.S. board-certified physicians in the recruitment process enhances communication and trust, which are critical for participant retention. By implementing these thorough recruitment strategies, sponsors can guarantee a diverse and representative sample, ultimately enhancing the credibility of study results.

    At bioaccess®, our founders-distinguished specialists like Dr. Martinez-Clark and Dr. O’Neill-bring their extensive expertise to expedite studies and tackle compliance hurdles in Latin America. Their dedication to closing the divide between medical innovation and research ensures that our clients can efficiently carry out studies in first in human biopharma Chile, benefiting from the strategic advantages of the region. Furthermore, adherence to local oversight bodies such as INVIMA is crucial to navigate the operational landscape effectively, ensuring that all recruitment strategies align with compliance requirements. By prioritizing these strategies, sponsors can not only enhance enrollment but also contribute to the future of medical research in Latin America.

    This mindmap starts with the main idea of patient recruitment strategies at the center. Each branch represents a key area of focus, and the sub-branches provide specific actions or considerations related to that area. Follow the branches to see how different strategies connect and contribute to successful recruitment.

    Select and Activate Clinical Trial Sites Efficiently

    Selecting the right clinical trial sites is crucial for the success of first in human biopharma Chile trials, yet many sponsors overlook this vital step. Sponsors should prioritize sites that have a solid understanding of local regulatory frameworks and a proven track record in conducting FIH studies, especially those that are first in human biopharma Chile and governed by the Instituto de Salud Pública (ISP). Engaging with these sites early in the planning phase leads to smoother activation. It opens the door for discussions about demographics, logistical considerations, and resource availability. Utilizing a network of pre-qualified sites can significantly expedite the activation process, reducing the time to first patient in, which typically lasts about 30 days according to industry standards.

    In Latin America, the benefits of conducting studies related to first in human biopharma Chile are substantial, with accelerated ethics approvals often achievable within 4-8 weeks. Make sure that sites are well-staffed and equipped to meet the study’s specific requirements and comply with ICH-GCP standards. Furthermore, sponsors should be aware of the submission routes for approvals, including the necessary documentation and timelines for compliance with the ISP and other relevant authorities such as INVIMA, ANVISA, and COFEPRIS. By concentrating on efficient site selection and activation strategies, sponsors can markedly enhance the overall timeline and success rate of their clinical trials, ultimately leading to faster regulatory approvals and improved patient outcomes.

    This flowchart guides you through the steps to select and activate clinical trial sites effectively. Follow the arrows to see how each step connects to the next, ensuring a smooth process from identifying needs to activating the site.

    Conclusion

    Navigating the complexities of first in human biopharma trials in Chile can be daunting, yet it presents unique opportunities for those who are prepared. A strategic approach is essential, encompassing:

    1. Understanding regulatory frameworks
    2. Conducting early feasibility studies
    3. Implementing effective patient recruitment strategies
    4. Selecting optimal clinical trial sites

    These best practices help streamline the research process. They also position sponsors to leverage Chile’s advantageous clinical landscape, characterized by efficient approval timelines and a growing reputation as a hub for biopharma research in Latin America.

    Key insights from this article highlight the importance of familiarizing oneself with the regulatory environment established by the Instituto de Salud Pública (ISP) and adhering to ICH-GCP standards. Early feasibility studies play a critical role in validating trial designs and ensuring patient safety. Targeted recruitment strategies are essential for achieving enrollment goals. Additionally, the careful selection and activation of clinical trial sites can significantly enhance the speed and success of studies, ultimately leading to faster regulatory approvals and improved patient outcomes.

    In conclusion, the strategic advantages of conducting first in human biopharma trials in Chile cannot be overstated. By embracing these best practices, sponsors can navigate the regulatory landscape more effectively and capitalize on the region’s unique strengths, such as diverse patient populations and rapid approval processes. This proactive approach is key to advancing medical innovation and making sure clinical research in Latin America thrives, ultimately benefiting the global healthcare community.

    Frequently Asked Questions

    What is the importance of understanding regulatory frameworks for first in human (FIH) trials in Chile?

    Understanding the regulatory landscape in Chile is crucial for sponsors to expedite their clinical research efforts, as it allows for efficient navigation of the approval process established by the Instituto de Salud Pública (ISP) and adherence to ICH-GCP standards.

    How long does the approval process for FIH trials typically take in Chile?

    The approval process for FIH trials in Chile typically takes around 30 business days, making it an attractive destination for sponsors seeking expedited timelines.

    What key regulations must sponsors be aware of when conducting FIH trials in Chile?

    Key regulations include Law No. 20.120, which emphasizes the necessity of informed consent and ethical oversight through accredited Scientific Ethics Committees (CECs).

    What are the essential components of a Clinical Trial Application (CTA) for FIH studies in Chile?

    A detailed Clinical Trial Application (CTA) should include thorough study protocols, patient safety measures, and robust data management plans.

    How does familiarity with regulatory guidelines benefit sponsors conducting FIH trials in Chile?

    Familiarity with regulatory guidelines simplifies the approval process and enhances the credibility of study data, which is crucial for subsequent submissions to authorities such as the FDA.

    What is Chile’s current ranking in Latin America regarding research studies as of 2024?

    As of 2024, Chile ranks fourth among Latin American nations for research studies, highlighting its growing importance in the field.

    Why is it essential for sponsors to act swiftly and strategically in Chile’s regulatory environment?

    The shift in research activity towards Chile underscores the need for sponsors to capitalize on the favorable conditions for successful first in human biopharma studies, ensuring they can leverage the country’s advantages in speed, cost efficiency, and patient recruitment.

    List of Sources

    1. Understand Regulatory Frameworks for FIH Trials in Chile
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOooTXyjSwEH4_QafBwJInZYKr08bzEQj6pveus93SvpyjGJzdo9s)
      • Navigate First in Human Medical Device Trials in Chile: A Step-by-Step Guide | bioaccess® (https://bioaccessla.com/blog/navigate-first-in-human-medical-device-trials-in-chile-a-step-by-step-guide)
      • bioaccessla.com (https://bioaccessla.com/blog/master-early-phase-clinical-trials-in-chile-key-strategies-and-insights)
    2. Conduct Early Feasibility Studies to Validate Trial Designs
      • inderes.dk (https://inderes.dk/en/articles/probabilities-of-success-in-drug-development)
      • Early feasibility studies on devices: “doing it sooner” to avoid trial failure | Meditrial (https://meditrial.net/2022/09/early-feasibility-studies-on-devices-doing-it-sooner-to-avoid-trial-failure)
      • insights.citeline.com (https://insights.citeline.com/IV154612/Why-Are-Clinical-Development-Success-Rates-Falling)
      • Early Feasibility Studies: Top 6 Considerations | MED Institute (https://medinstitute.com/blog/early-feasibility-studies-top-6-considerations)
    3. Implement Targeted Patient Recruitment Strategies
      • Patient Recruitment and Retention in Clinical Trials: Strategies and Challenges (https://mdgroup.com/blog/patient-recruitment-and-retention-in-clinical-trials-strategies-and-challenges)
      • clariness.com (https://clariness.com/resource/3-patient-recruitment-strategies-in-clinical-trials)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC11348161)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • Patient Recruitment for Clinical Trials: Strategies That Actually Work (https://kapsuletech.com/blog/patient-recruitment-clinical-trials)
    4. Select and Activate Clinical Trial Sites Efficiently
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • statista.com (https://statista.com/statistics/1560150/chile-number-new-clinical-trials?srsltid=AfmBOorIgx9EusEA1UXDnMlDFfoY348h5b3ULrkxL-dycroOn2uLWUjd)
      • bioaccessla.com (https://bioaccessla.com/blog/master-early-phase-clinical-trials-in-chile-key-strategies-and-insights)
      • 70 Research Quotes to Inspire Your Work – Qualtrics (https://qualtrics.com/articles/strategy-research/research-quotes)
      • blog.investchile.gob.cl (https://blog.investchile.gob.cl/clinical-trials-investment-in-chile)

  • Conducting First-in-Human Clinical Trials in Chile: A Step-by-Step Guide

    Conducting First-in-Human Clinical Trials in Chile: A Step-by-Step Guide

    Introduction

    While Chile offers a promising landscape for first-in-human clinical trials, the path is fraught with challenges that demand careful navigation.

    With its streamlined regulatory processes and robust healthcare infrastructure, Chile stands out as a strategic location for early-stage clinical research.

    However, navigating these complexities can hinder progress and delay trial timelines.

    By understanding these challenges, researchers can turn potential obstacles into strategic advantages.

    Understand Regulatory Requirements for FIH Trials in Chile

    To successfully conduct a first-in-human clinical trial in Chile, understanding the compliance framework is not just beneficial – it’s essential. Here are the essential steps to follow:

    1. Identify Regulatory Authorities: The Instituto de Salud Pública (ISP) is the main regulatory organization supervising clinical studies in Chile. Familiarize yourself with their guidelines and requirements to ensure compliance.
    2. Review Relevant Legislation: Key laws, including Law No. 20.120, govern human research and the Sanitary Code, outlining the ethical and procedural standards necessary for conducting studies.
    3. Prepare Required Documentation: Gather key documents like the clinical study protocol, informed consent forms, and qualifications of your investigators. Ensure all documents comply with ICH-GCP standards to facilitate approval.
    4. Submit to Ethics Committees: Obtain approval from an accredited Scientific Ethics Committee (CEC) before submitting to the ISP. This step is vital for ensuring ethical compliance and safeguarding patient welfare.
    5. Submit Application to ISP: After securing CEC approval, submit your application to the ISP. The review process typically takes about 30 days. Ensure your submission includes all required documentation to prevent delays.
    6. Understand FDA Acceptance: If you plan to submit data to the FDA, ensure your study design aligns with their requirements for acceptance of foreign clinical data under 21 CFR 812.28.

    Navigating the compliance framework can be daunting, especially for first-time researchers involved in the first-in-human clinical trial in Chile. By following these steps, you not only ensure compliance but also enhance the likelihood of a successful study outcome. The ISP’s dedication to regulatory speed and efficiency, along with the country’s robust healthcare infrastructure, establishes it as a strategic advantage for early-stage clinical research.

    Each box represents a step in the process of conducting a first-in-human clinical trial in Chile. Follow the arrows to see how each step leads to the next, ensuring you complete them in order for a successful trial.

    Select and Prepare Clinical Trial Sites in Chile

    Selecting the right clinical research locations is a critical factor that can determine the success of your first-in-human clinical trial in Chile. Here’s a structured approach to ensure effective site selection and preparation:

    1. Identify Potential Locations: Start by recognizing clinical locations with a demonstrated history in FIH studies. Look for facilities that have successfully conducted similar studies and show a track record of compliance and quality outcomes.
    2. Evaluate Location Capabilities: Assess each location’s capabilities, focusing on their infrastructure, staff qualifications, and patient access. Ensure that the location can meet the specific needs of your study protocol, including essential medical equipment and qualified personnel.
    3. Conduct Feasibility Studies: Perform comprehensive feasibility studies to assess the location’s capability to recruit the necessary number of participants within your desired timeline. Understanding local demographics can be challenging, yet it is essential for effective recruitment, especially in a context where Chile has streamlined its clinical study approval processes, reducing bureaucratic delays by over 30% (Instituto de Salud Pública, 2026). Early feasibility studies can further reduce risks in medical device development, allowing for a more informed approach to location selection.
    4. Prepare Location for Testing Execution: After selecting the locations, ready them for testing execution by training staff on the protocol and ensuring adherence to ICH-GCP guidelines. This preparation includes setting up necessary equipment and resources to facilitate smooth operations.
    5. Establish Communication Channels: Create clear communication pathways between the sponsor, staff at the location, and regulatory bodies such as INVIMA. Regular updates and meetings are essential for addressing any issues that may arise during the study, fostering collaboration and commitment.
    6. Monitor Site Readiness: Prior to trial initiation, conduct site visits to confirm that all preparations are complete and that the site is fully equipped to start enrolling participants. This proactive approach helps reduce delays and ensures that you meet industry standards.

    As Julio G. Martinez-Clark, CEO of bioaccess® regulatory, highlights, “In the dynamic landscape of clinical research, navigating the regulatory framework in this region is crucial for success.” By prioritizing strategic site selection and preparation, you position your study as a first-in-human clinical trial in Chile for optimal success in the competitive landscape of clinical research. Moreover, consider the pediatric population, which makes up 30% of the residents in Chile, as an important patient group that could be approached for studies with customized recruitment strategies.

    Each box represents a crucial step in preparing for a clinical trial. Follow the arrows to see how each step leads to the next, ensuring a thorough and organized approach to site selection.

    Implement Effective Patient Recruitment Strategies

    Recruiting patients for first-in-human studies is not just a task; it’s a critical challenge that can determine the success of groundbreaking medical advancements. Effective patient recruitment is essential for the success of your first-in-human (FIH) study. Here are strategies to enhance recruitment efforts, particularly when leveraging bioaccess®’s Innovation Runway:

    1. Leverage Local Networks: Collaborate with local healthcare providers and institutions to identify potential participants. Building relationships with physicians can facilitate referrals, ensuring that you tap into established patient bases. For instance, the FM-TIPS study demonstrated that engaging local providers significantly increased referrals and highlighted the necessity of building trust and communication between researchers and community healthcare professionals.
    2. Utilize Community Engagement: By engaging with the community through informational sessions, health fairs, and local events, you not only raise awareness about the study but also build trust and interest among potential participants. Notably, community engagement efforts have shown that average monthly inquiries across clinics increased from 2.15 inquiries per month prior to engagement to 28.07 inquiries per month after implementing these strategies.
    3. Implement Digital Marketing: Use digital marketing strategies, including social media campaigns and targeted online ads, to reach a broader audience. Emphasize the study’s purpose and potential advantages to generate interest. Successful campaigns have demonstrated significant increases in inquiries and engagement, showcasing the power of online outreach.
    4. Create Patient-Centric Materials: Develop clear and informative resources that describe the study process, potential risks, and benefits. Ensure that these materials are culturally sensitive and available in Spanish to resonate with the local population. This approach aligns with the need for effective communication in diverse communities.
    5. Offer Incentives: Consider providing incentives for participation, such as travel reimbursements or health check-ups. This can inspire individuals to sign up and stay involved throughout the study, addressing potential obstacles to participation. However, it is essential to ensure that compensation is appropriate to avoid perceptions of coercion.
    6. Monitor Recruitment Progress: Regularly assess recruitment metrics to identify any challenges or delays. Adjust strategies as needed to ensure that enrollment targets are met on time. Continuous monitoring allows for timely interventions, enhancing overall recruitment efficiency.

    Without effective recruitment strategies, the potential benefits of innovative treatments may never reach those who need them most. By embracing these strategies, you not only enhance recruitment but also pave the way for innovations, such as those arising from the first-in-human clinical trial in Chile, that could transform patient care in Chile and beyond. Additionally, understanding the regulatory landscape, including the streamlined assessment process outlined in Law 14.874/24, can further capitalize on the region’s unique advantages in speed, cost efficiency, and compliance pathways.

    This mindmap shows various strategies for recruiting patients in clinical studies. Each branch represents a different approach, and you can follow the lines to see how they connect to the main goal of effective recruitment.

    Monitor Trial Progress and Manage Data Effectively

    In the high-stakes environment of the first-in-human clinical trial in Chile, effective monitoring and data management are not just beneficial – they’re essential for success. To ensure effective oversight, consider these critical steps:

    1. Establish Monitoring Plans: Create a detailed monitoring plan that outlines the frequency and methods for overseeing activities, patient safety, and data integrity, aligning with ICH-GCP guidelines.
    2. Utilize Data Management Systems: Implement a robust clinical data management system (CDMS) that streamlines data collection, storage, and analysis while ensuring adherence to standards set by authorities such as ANVISA and COFEPRIS.
    3. Conduct Regular Visits: Schedule frequent visits to assess adherence to the trial protocol and compliance requirements. These visits should also provide support to site staff and address any emerging issues promptly.
    4. Track Patient Safety: Vigilantly monitor patient safety by reviewing adverse event reports and ensuring that all incidents are documented and reported to the relevant oversight bodies, such as INVIMA.
    5. Analyze Data Continuously: Engage in ongoing data analysis to identify trends and potential issues. This proactive approach enables timely interventions and necessary adjustments to the study protocol.
    6. Prepare for Audits: Organize all documentation for easy access during audits by regulatory authorities. This involves maintaining precise records of study activities, patient consent forms, and data entries to ensure compliance and transparency.

    Neglecting these steps could jeopardize not only the trial’s integrity but also patient safety, making adherence to these guidelines imperative.

    Each box represents a step in the process of monitoring and managing data during a clinical trial. Follow the arrows to see the order in which these steps should be taken to ensure success and safety.

    Conclusion

    Navigating first-in-human clinical trials in Chile presents unique challenges that demand a strategic approach. Successfully navigating these trials requires a solid grasp of regulatory frameworks. It also demands strategic site selection, effective patient recruitment, and diligent monitoring of trial progress. By following the outlined step-by-step guide, researchers can streamline their approach, ensuring compliance and maximizing the potential for successful outcomes in this vital phase of clinical research.

    Key insights from this guide emphasize the importance of engaging with regulatory authorities like the Instituto de Salud Pública (ISP) and adhering to ethical standards set by Scientific Ethics Committees. Additionally, selecting appropriate clinical trial sites and employing innovative recruitment strategies are crucial for attracting participants and maintaining momentum throughout the study. Navigating the complex regulatory landscape and ensuring effective patient recruitment can be daunting for researchers. The proactive management of trial data and patient safety monitoring further reinforces the integrity and reliability of the research process.

    Embracing the advantages of conducting first-in-human trials in Chile – such as expedited approval timelines, robust healthcare infrastructure, and a diverse patient population – positions researchers to make significant strides in medical innovation. When stakeholders apply these best practices, they truly help create a thriving clinical research environment that enhances patient care in Chile and sets a model for successful trials across Latin America.

    Frequently Asked Questions

    What is the main regulatory authority for clinical trials in Chile?

    The main regulatory authority supervising clinical studies in Chile is the Instituto de Salud Pública (ISP).

    What key legislation governs human research in Chile?

    Key legislation includes Law No. 20.120 and the Sanitary Code, which outline the ethical and procedural standards necessary for conducting studies.

    What documentation is required to conduct a first-in-human clinical trial in Chile?

    Required documentation includes the clinical study protocol, informed consent forms, and qualifications of investigators, all of which must comply with ICH-GCP standards.

    What is the process for obtaining ethical approval for a clinical trial in Chile?

    Researchers must obtain approval from an accredited Scientific Ethics Committee (CEC) before submitting their application to the ISP. This step is crucial for ensuring ethical compliance and patient welfare.

    How long does the ISP take to review applications for clinical trials?

    The review process typically takes about 30 days once the application is submitted to the ISP.

    What should be considered if planning to submit data to the FDA?

    If planning to submit data to the FDA, ensure that the study design aligns with their requirements for acceptance of foreign clinical data under 21 CFR 812.28.

    Why is understanding the compliance framework essential for first-in-human trials in Chile?

    Understanding the compliance framework is essential to ensure regulatory adherence, enhance the likelihood of a successful study outcome, and navigate the complexities of conducting clinical trials in Chile effectively.

    What advantages does Chile offer for early-stage clinical research?

    Chile offers advantages such as regulatory speed and efficiency, a robust healthcare infrastructure, and cost-effective patient recruitment, making it a strategic location for early-stage clinical trials.

    List of Sources

    1. Understand Regulatory Requirements for FIH Trials in Chile
      • Chile Clinical Trial Regulations | ISP Guide | bioaccess® (https://bioaccessla.com/regulatory-guide/chile)
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • First-in-Human Medical Device Trial in Chile | bioaccess® (https://bioaccessla.com/blog/first-in-human-medical-device-trial-chile)
      • pharmaregulatory.in (https://pharmaregulatory.in/country-specific-regulatory-affairs/chile-isp-instituto-de-salud-publica)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
    2. Select and Prepare Clinical Trial Sites in Chile
      • bioaccessla.com (https://bioaccessla.com/blog/clinical-trial-site-selection-latin-america-key-strategies)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • reedintelligence.com (https://reedintelligence.com/market-analysis/chile-first-in-human-clinical-trial-market)
      • noymed.com (https://noymed.com/~noymedco/conducting-site-selection-the-key-factors-and-strategies-in-site-selection-for-clinical-trials)
      • Clinical Trial Site Selection: Key Challenges & Solutions for Phase 3 Success (https://precisionformedicine.com/blog/clinical-trial-site-selection-key-challenges-solutions-for-phase-3-success)
    3. Implement Effective Patient Recruitment Strategies
      • Community engagement is key to clinical trial recruitment and diversity (https://statnews.com/2019/08/23/clinical-trial-recruitment-diversity-community-engagement)
      • Improving Recruitment Through Community Engagement (https://clinicalleader.com/doc/improving-recruitment-through-community-engagement-0001)
      • Checking your browser – reCAPTCHA (https://pmc.ncbi.nlm.nih.gov/articles/PMC12444702)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • 10 Inspiring Patient Experience Quotes | Relias (https://relias.com/blog/patient-experience-quotes)
    4. Monitor Trial Progress and Manage Data Effectively
      • usnews.com (https://usnews.com/news/us/articles/2026-04-28/us-fda-to-monitor-clinical-trial-data-in-real-time-in-pilot-program-aimed-at-speeding-approvals)
      • Quotes Related to Data and Data Governance (https://blog.idatainc.com/quotes-related-to-data-and-data-governance)
      • drugs.com (https://drugs.com/news/fda-moves-real-time-clinical-trial-patient-monitoring-faster-review-129839.html)
      • pipeline.zoominfo.com (https://pipeline.zoominfo.com/operations/19-inspirational-quotes-about-data)
      • Importance of Clinical Data Management in Clinical Trials (https://sofpromed.com/importance-of-clinical-data-management-in-clinical-trials)

  • Master Early Phase Clinical Trials in Chile: Key Strategies and Insights

    Master Early Phase Clinical Trials in Chile: Key Strategies and Insights

    Introduction

    The initial phases of clinical trials are crucial, laying the groundwork for transformative medical advancements in Chile’s dynamic landscape. By capitalizing on a supportive regulatory environment and a diverse patient base, sponsors can unlock significant advantages in speed and cost efficiency when conducting early phase clinical trials. Navigating the complexities of compliance and patient recruitment poses significant challenges for sponsors. This article explores essential strategies that streamline the trial process and position Chile as a strategic hub for early phase clinical research in Latin America.

    Define Early Phase Clinical Trials and Their Importance in Chile

    In the realm of clinical research, the initial phases of studies are not just steps; they are critical milestones that determine the future of medical innovation. Initial phase clinical studies, specifically Phase I and II, represent the foundational stages for assessing new medical treatments, drugs, or devices in human subjects. These assessments are crucial for establishing safety, tolerability, pharmacokinetics, and preliminary efficacy. In this nation, the importance of early phase studies is heightened by the robust oversight framework, which includes adherence to ICH-GCP standards and efficient pathways for submissions through agencies like the Instituto de Salud Pública (ISP). This framework not only facilitates faster patient recruitment but also lowers operational costs when compared to the U.S. and Europe.

    How can sponsors leverage the regulatory environment designed for rapid approvals, with timelines often ranging from 30 to 90 days for initial submissions? Conducting these trials in Chile allows sponsors to tap into a diverse patient population, enhancing recruitment potential. Local investigators are not just cooperative; they are well-qualified and deeply familiar with the nuances of clinical research, making collaboration smoother.

    Additionally, the cost-efficiency of performing studies in this region is a notable benefit. By leveraging local resources and expertise, sponsors can achieve first-in-human milestones more efficiently, preserving capital and extending their operational runway. With bioaccess®, companies can save around $25K per patient through pre-negotiated site contracts and experience overall study costs that are 30% lower than in other regions. The blend of a supportive policy environment and a robust patient-physician rapport boosts adherence and speeds up the research development process, positioning the country as an appealing choice for early phase studies in Latin America. As the landscape of clinical research evolves, embracing the advantages of early phase clinical trial Chile could redefine success for many sponsors.

    This mindmap starts with the main topic in the center and branches out to show the key themes related to early phase clinical trials. Each branch represents a different aspect, making it easy to see how they connect and contribute to the overall importance of these trials in Chile.

    Explore Regulatory Requirements for Early Phase Trials in Chile

    Navigating the regulatory landscape in Chile is crucial for successful clinical research. Sponsors must submit a comprehensive application to initiate an early phase clinical trial in Chile. This application includes:

    1. The study protocol
    2. Informed consent forms
    3. Approvals from an accredited ethics committee

    Typically, the approval process lasts 30 to 60 days, depending on the study’s complexity. The ISP usually assesses applications within 30 business days. Compliance with ICH-GCP guidelines is mandatory, and all documentation must be translated into Spanish to meet local requirements. Additionally, securing an Import License for any investigational products is essential, with the process for obtaining this license taking approximately 2 to 4 weeks. Other pertinent oversight bodies, such as INVIMA, ANVISA, and COFEPRIS, may also have a role depending on the nature of the study and the products involved.

    How can sponsors navigate these compliance pathways more efficiently? By leveraging bioaccess®’s expertise, they can reduce delays and ensure a smooth study initiation. The expedited ethics approvals and early feasibility studies provided by bioaccess® enhance the efficiency of research in the region, positioning Latin America, particularly Chile, as a strategic advantage for MedTech and Biopharma companies conducting early phase clinical trials in Chile. Understanding these processes not only streamlines research but also positions companies for success in a competitive market.

    This flowchart outlines the steps sponsors need to follow to initiate early phase clinical trials in Chile. Each box represents a key step in the process, and the arrows show the order in which these steps should be completed. The timeframes mentioned help you understand how long each step might take.

    Implement Strategies for Successful Execution of Early Phase Trials

    Navigating the regulatory landscape for early phase clinical trial Chile can be daunting, but strategic partnerships can pave the way for success. To ensure effective implementation, sponsors should consider the following strategies:

    1. Engage Local Experts: Partner with specialized CROs like bioaccess®, the only CRO built exclusively for first-in-human trials. This collaboration simplifies the approval process, allowing for quicker navigation of compliance complexities. With the Public Health Institute of Chile (ISP) known for its efficient review processes, approvals for early phase clinical trial Chile can be secured in as little as 4-8 weeks, compared to the 6+ months often seen in the US/EU.
    2. Leverage Patient Recruitment Networks: Utilize bioaccess®’s established networks to enhance patient recruitment efforts. This ensures a diverse participant pool that accurately reflects the target population. With 80% treatment-naïve patient populations and 50% faster enrollment, bioaccess® can help you efficiently meet your recruitment goals.
    3. Streamline Protocol Development: Develop clear and concise study protocols that align with compliance expectations, such as ICH-GCP adherence. bioaccess®’s expertise guarantees that your protocols meet the required standards for FDA acceptance, utilizing the Innovation Runway to expedite milestones in the trial process.
    4. Implement Risk-Based Monitoring: Adopt risk-based monitoring strategies to ensure compliance and data integrity while minimizing costs. By employing these strategies, sponsors can enhance their operational efficiency and reduce time to market, ultimately preserving equity and extending their runway for further R&D investments.

    By embracing these strategies, sponsors not only enhance their operational efficiency but also position themselves for sustainable growth in the competitive Medtech landscape.

    Each box represents a strategy to enhance the execution of early phase trials. Follow the arrows to see how each strategy builds on the previous one, guiding sponsors toward successful trial outcomes.

    Identify and Overcome Challenges in Early Phase Clinical Trials

    Navigating the complexities of early phase clinical trial Chile presents significant challenges that demand strategic foresight. Approval delays, patient recruitment difficulties, and logistical issues can significantly hinder the progress of early phase clinical trial Chile. To tackle these obstacles effectively, sponsors need to consider several key strategies:

    1. Anticipate Regulatory Changes: Stay informed about evolving regulations from the Instituto de Salud Pública (ISP) and engage with them early in the process to mitigate potential compliance issues. Recent regulatory modifications, including Law 14.874/24, which was approved in May 2024, aim to simplify the assessment process, minimizing bureaucratic hurdles and improving predictability in approval processes. With Bioaccess® on your side, you’ll be well-prepared for these changes.
    2. Enhance Patient Engagement: Develop targeted outreach programs to educate potential participants about the benefits of the study, which can significantly improve recruitment rates. Given that dropout rates in Latin America are one-third of those in the U.S. and EU, fostering strong relationships between patients and physicians can enhance retention. Bioaccess® has successfully navigated these challenges, helping clients engage effectively with local populations.
    3. Optimize Site Selection: Choose research sites with demonstrated success in early phase studies to ensure efficient operations and effective patient management. Chile’s urban centers provide a concentrated subject pool, making it easier to recruit participants who are often eager to engage in early phase clinical trial Chile. Bioaccess®’s extensive network can assist in identifying the most suitable sites.
    4. Utilize Technology: Implement digital tools for data collection and monitoring to streamline processes and enhance communication among stakeholders. Utilizing technology can assist in overcoming logistical difficulties and enhancing overall study efficiency. Bioaccess® utilizes cutting-edge technological solutions to enable smoother study operations.

    By leveraging local expertise and innovative strategies, sponsors can turn these challenges into opportunities for success in clinical research.

    This flowchart shows the main challenges faced in early phase clinical trials and the strategies to overcome them. Follow the arrows to see how each challenge connects to a specific solution, helping you understand the process of navigating these complexities.

    Conclusion

    Navigating the complexities of early phase clinical trials in Chile presents both challenges and opportunities for sponsors in the MedTech and Biopharma sectors. These initial studies, which include Phase I and II, are crucial for laying the groundwork for future medical advancements. The unique regulatory environment in Chile, with its efficient approval timelines and supportive infrastructure, makes the country an attractive destination for conducting these trials. This enables sponsors to achieve significant milestones swiftly and cost-effectively.

    What strategies can enhance the success of early phase trials in Chile? Here are several key tactics to consider:

    1. Engaging local experts
    2. Leveraging patient recruitment networks
    3. Streamlining protocol development
    4. Implementing risk-based monitoring

    These critical tactics can mitigate challenges and optimize operational efficiency. Moreover, understanding the regulatory landscape, including compliance with ICH-GCP guidelines and navigating the approval process with the ISP, is fundamental for ensuring a smooth trial initiation and execution.

    As the clinical research landscape continues to evolve, embracing the advantages offered by early phase clinical trials in Chile is essential for sponsors aiming to achieve a competitive edge. Reduced operational costs, faster patient recruitment, and a robust regulatory framework accelerate the path to market and foster innovation in medical treatments. By capitalizing on these insights and strategies, stakeholders can effectively navigate the complexities of early phase trials, ultimately contributing to the advancement of healthcare solutions in Latin America and beyond. By not seizing these opportunities, sponsors risk falling behind in the rapidly evolving landscape of medical innovation.

    Frequently Asked Questions

    What are early phase clinical trials and why are they important in Chile?

    Early phase clinical trials, specifically Phase I and II, are critical milestones in clinical research that assess new medical treatments, drugs, or devices in human subjects. They are essential for establishing safety, tolerability, pharmacokinetics, and preliminary efficacy, making them foundational for future medical innovation.

    How does the regulatory environment in Chile support early phase clinical trials?

    Chile has a robust oversight framework that adheres to ICH-GCP standards and provides efficient submission pathways through agencies like the Instituto de Salud Pública (ISP). This environment facilitates faster patient recruitment and reduces operational costs compared to the U.S. and Europe.

    What are the benefits of conducting early phase clinical trials in Chile?

    Conducting trials in Chile allows sponsors to access a diverse patient population, enhancing recruitment potential. The cost-efficiency of studies in this region is notable, with companies able to save around $25K per patient and experience overall study costs that are 30% lower than in other regions.

    What is the typical timeline for initial submissions for early phase trials in Chile?

    The typical timeline for initial submissions in Chile ranges from 30 to 90 days, allowing for rapid approvals and facilitating quicker progression of clinical studies.

    How do local investigators contribute to the success of early phase trials in Chile?

    Local investigators in Chile are well-qualified and familiar with the nuances of clinical research, which makes collaboration smoother and enhances the overall efficiency of conducting trials.

    What financial advantages do sponsors gain from conducting early phase trials in Chile?

    By leveraging local resources and expertise, sponsors can achieve first-in-human milestones more efficiently, preserving capital and extending their operational runway, thereby enhancing the overall financial viability of their clinical studies.

    How does the relationship between patients and physicians in Chile impact clinical research?

    The strong rapport between patients and physicians in Chile boosts adherence to clinical trials and speeds up the research development process, making the country an appealing choice for early phase studies in Latin America.

    List of Sources

    1. Define Early Phase Clinical Trials and Their Importance in Chile
      • grandviewresearch.com (https://grandviewresearch.com/horizon/outlook/clinical-trials-market/latin-america)
      • Early Feasibility Studies in Latin America (https://greenlight.guru/blog/early-feasibility-studies-in-latin-america)
      • clinicaltrialsarena.com (https://clinicaltrialsarena.com/news/clinical-trials-considerations-for-latin-america-5813786-2)
    2. Explore Regulatory Requirements for Early Phase Trials in Chile
      • Master the Clinical Trial Approval Process in Chile | bioaccess® (https://bioaccessla.com/blog/master-the-clinical-trial-approval-process-in-chile)
      • pharmaregulatory.in (https://pharmaregulatory.in/country-specific-regulatory-affairs/chile-isp-instituto-de-salud-publica)
      • Master Regulatory Compliance For Trials In Chile Effectively | bioaccess® (https://bioaccessla.com/blog/master-regulatory-compliance-for-trials-in-chile-effectively)
      • Chile Clinical Trial Regulations | ISP Guide | bioaccess® (https://bioaccessla.com/regulatory-guide/chile)
    3. Implement Strategies for Successful Execution of Early Phase Trials
      • reedintelligence.com (https://reedintelligence.com/market-analysis/chile-first-in-human-clinical-trial-market)
      • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)
      • The Importance of Patient Recruitment in Clinical Trials | Novotech CRO (https://novotech-cro.com/blog/importance-patient-recruitment-clinical-trials)
      • FDA Issues Guidance on Modernizing Statistical Methods for Clinical Trials (https://fda.gov/news-events/press-announcements/fda-issues-guidance-modernizing-statistical-methods-clinical-trials)
      • appliedclinicaltrialsonline.com (https://appliedclinicaltrialsonline.com/view/optimizing-early-phase-clinical-trials-to-minimize-risk-and-improve-decision-making)
    4. Identify and Overcome Challenges in Early Phase Clinical Trials
      • 7 quotes from 2023 to guide you on the medtech market (https://tiinatyni.com/blogi/7-quotes-from-2023-to-guide-you-on-the-medtech-market)
      • Latin America: A Compelling Region To Conduct Your Clinical Trials (https://clinicalleader.com/doc/latin-america-a-compelling-region-to-conduct-your-clinical-trials-0001)
      • goodreads.com (https://goodreads.com/quotes/tag/clinical-trials)
      • Clinical Trials Patient Recruitment in Latin America | H Clinical (https://hclinical.com/patient-recruitment)